Cipla
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
By Rishika Sadam
June 12 (Reuters) - India's drug price regulator raised ceiling rates for two key platinum-based cancer drugs by 50% after a surge in raw material costs triggered widespread shortages, according to a government notification seen by Reuters.
The National Pharmaceutical Pricing Authority invoked special provisions to raise rates for the drugs after receiving federal government approval citing public interest, according to the notification dated June 11.
Patients in the world's most populous country have been grappling with shortages of platinum-based cancer drugs cisplatin and carboplatin, as hospitals, especially government-run facilities, run short.
The prices of the drugs, used to treat ovarian, lung and bladder cancers, are capped and controlled by the government.
The ceiling rate for cisplatin was raised to 10.89 rupees ($0.1144) per ml from 7.26 rupees, while that for carboplatin was increased to 90.74 rupees ($0.9530) per ml from 60.49 rupees excluding taxes, the notification showed.
"... The authority noted concerns regarding shortage and supply disruptions of carboplatin and cisplatin formulations, which are essential oncology medicines used in the treatment of various cancers," the NPPA said, adding that their uninterrupted availability is critical for public health.
The drugs are manufactured by several companies, including Cipla CIPL.NS, Intas Pharmaceuticals and oncology-focused firms such as Naprod Life Sciences and Venus Remedies VENR.NS.
The increase is a one-time revision and will be reviewed after six months, the NPPA said.
India is heavily dependent on imported platinum, which is used in industries ranging from automobiles and jewellery to chemicals and pharmaceuticals.
Supplies of the white metal from key producers such as South Africa have dwindled amid soaring costs, while the Middle East conflict has further disrupted supply chains and raised manufacturing expenses, doctors and industry executives have told Reuters.
The increase on drug price caps offers relief to medicine makers who had temporarily halted production as platinum prices more than doubled amid tight supplies, strong demand and shrinking inventories.
($1 = 95.2150 Indian rupees)
(Reporting by Rishika Sadam, Additional reporting by Abhinav Parmar in Bengaluru; Editing by Nivedita Bhattacharjee)
By Rishika Sadam
June 12 (Reuters) - India's drug price regulator raised ceiling rates for two key platinum-based cancer drugs by 50% after a surge in raw material costs triggered widespread shortages, according to a government notification seen by Reuters.
The National Pharmaceutical Pricing Authority invoked special provisions to raise rates for the drugs after receiving federal government approval citing public interest, according to the notification dated June 11.
Patients in the world's most populous country have been grappling with shortages of platinum-based cancer drugs cisplatin and carboplatin, as hospitals, especially government-run facilities, run short.
The prices of the drugs, used to treat ovarian, lung and bladder cancers, are capped and controlled by the government.
The ceiling rate for cisplatin was raised to 10.89 rupees ($0.1144) per ml from 7.26 rupees, while that for carboplatin was increased to 90.74 rupees ($0.9530) per ml from 60.49 rupees excluding taxes, the notification showed.
"... The authority noted concerns regarding shortage and supply disruptions of carboplatin and cisplatin formulations, which are essential oncology medicines used in the treatment of various cancers," the NPPA said, adding that their uninterrupted availability is critical for public health.
The drugs are manufactured by several companies, including Cipla CIPL.NS, Intas Pharmaceuticals and oncology-focused firms such as Naprod Life Sciences and Venus Remedies VENR.NS.
The increase is a one-time revision and will be reviewed after six months, the NPPA said.
India is heavily dependent on imported platinum, which is used in industries ranging from automobiles and jewellery to chemicals and pharmaceuticals.
Supplies of the white metal from key producers such as South Africa have dwindled amid soaring costs, while the Middle East conflict has further disrupted supply chains and raised manufacturing expenses, doctors and industry executives have told Reuters.
The increase on drug price caps offers relief to medicine makers who had temporarily halted production as platinum prices more than doubled amid tight supplies, strong demand and shrinking inventories.
($1 = 95.2150 Indian rupees)
(Reporting by Rishika Sadam, Additional reporting by Abhinav Parmar in Bengaluru; Editing by Nivedita Bhattacharjee)
June 11 (Reuters) - Cipla Ltd CIPL.NS:
USFDA CLASSIFIED VERNA MANUFACTURING FACILITY INSPECTION AS VOLUNTARY ACTION INDICATED
Source text: ID:nnAZN4T1SB5
Further company coverage: CIPL.NS
(([email protected];;))
June 11 (Reuters) - Cipla Ltd CIPL.NS:
USFDA CLASSIFIED VERNA MANUFACTURING FACILITY INSPECTION AS VOLUNTARY ACTION INDICATED
Source text: ID:nnAZN4T1SB5
Further company coverage: CIPL.NS
(([email protected];;))
By Rishika Sadam
June 9 (Reuters) - Kumar Ajit spent more than a week calling dozens of pharmacies in India before he tracked down the platinum-based cancer drug cisplatin his 70-year old mother needed to treat her liver cancer.
"I could not even get the desired dosage," added Ajit, who eventually found the medicine in New Delhi, the capital, and had it shipped to his village in the eastern state of Bihar. "I'm unsure what I will do for the next dose."
The 52-year-old bank employee's struggle highlights India's growing shortage of platinum-based cancer drugs, forcing patients to hunt for supplies as hospitals run short, especially those run by the government.
India relies on imported platinum, with key supplies from countries such as South Africa drying up on a surge in prices as well as disruptions from conflict in the Middle East, doctors and industry executives said.
"There has been a supply crunch for two months, but it has become worse over the last two weeks with a shortage," said Rajiv Singhal, general secretary of the All India Organisation of Chemists and Druggists, with 1.24 million members.
"Drug distributors have been calling us complaining that they're not getting these drugs."
A range of generic drugmakers turns out India's platinum-based chemotherapy, such as Cipla CIPL.NS and Intas Pharmaceuticals INTA.NS, he said, along with smaller oncology specialists like Naprod Life Sciences and Venus Remedies VENR.NS.
Doctors and drug distributors said supplies of drugs such as cisplatin and carboplatin, used to treat cancers of the lung, ovaries and gall bladder, have been tight in recent weeks.
"I get about 10 calls a day from patients asking for help with cisplatin," said Pavan Kumar of Kethan Pharma Distributors in the southern tech hub of Hyderabad.
Doctors estimate at least a quarter of India's chemotherapy patients have been prescribed platinum-based drugs.
"They have been a backbone for cancer treatment," said Mintu Mathew Abraham, a consultant oncologist at PRS Hospital in the southern coastal state of Kerala. "Without them, it would be hard to continue treatment."
Platinum prices have rallied on expectations of a fourth consecutive year of market deficits, driven by constrained mine supply, robust investment demand and dwindling inventories as the metal replaces palladium in automotive applications.
DRUGMAKERS SEEK PRICE REVISION
Drugmakers are unable to pass on higher costs as the government caps the prices of the medicines, though they have sought an increase of roughly 50% in the price caps.
India's pharmaceuticals department did not respond to requests for comment.
Some manufacturers have cut production.
The struggle to find platinum-based raw material has prompted Naprod Life Sciences to temporarily halt output of cisplatin and carboplatin, for example.
"The shortage is primarily driven by a steep increase in platinum prices," said company director Mohan Jain, adding that prices over the past year have jumped to 5,000 rupees ($52.30) for one gram from about 2,000 rupees.
Venus Remedies, which supplies to government hospitals, said it has been absorbing losses but is now cautious about taking on new contracts.
"If those caps are not adjusted in line with rising costs, the supply chain comes under pressure," said Executive Director Saransh Chaudhary. "Companies cannot absorb the full increase, so patients ultimately bear the impact and shortages persist."
The other drugmakers did not respond to Reuters requests for comment.
There are few alternatives to the platinum-based cancer drugs, and substitutes can be less effective or more toxic, said oncologist Venkateshwar Rao at Omega Hospital in the southern state of Andhra Pradesh.
($1=95.6000 rupees)
(Reporting by Rishika Sadam; Editing by Dhanya Skariachan and Clarence Fernandez)
(([email protected];))
By Rishika Sadam
June 9 (Reuters) - Kumar Ajit spent more than a week calling dozens of pharmacies in India before he tracked down the platinum-based cancer drug cisplatin his 70-year old mother needed to treat her liver cancer.
"I could not even get the desired dosage," added Ajit, who eventually found the medicine in New Delhi, the capital, and had it shipped to his village in the eastern state of Bihar. "I'm unsure what I will do for the next dose."
The 52-year-old bank employee's struggle highlights India's growing shortage of platinum-based cancer drugs, forcing patients to hunt for supplies as hospitals run short, especially those run by the government.
India relies on imported platinum, with key supplies from countries such as South Africa drying up on a surge in prices as well as disruptions from conflict in the Middle East, doctors and industry executives said.
"There has been a supply crunch for two months, but it has become worse over the last two weeks with a shortage," said Rajiv Singhal, general secretary of the All India Organisation of Chemists and Druggists, with 1.24 million members.
"Drug distributors have been calling us complaining that they're not getting these drugs."
A range of generic drugmakers turns out India's platinum-based chemotherapy, such as Cipla CIPL.NS and Intas Pharmaceuticals INTA.NS, he said, along with smaller oncology specialists like Naprod Life Sciences and Venus Remedies VENR.NS.
Doctors and drug distributors said supplies of drugs such as cisplatin and carboplatin, used to treat cancers of the lung, ovaries and gall bladder, have been tight in recent weeks.
"I get about 10 calls a day from patients asking for help with cisplatin," said Pavan Kumar of Kethan Pharma Distributors in the southern tech hub of Hyderabad.
Doctors estimate at least a quarter of India's chemotherapy patients have been prescribed platinum-based drugs.
"They have been a backbone for cancer treatment," said Mintu Mathew Abraham, a consultant oncologist at PRS Hospital in the southern coastal state of Kerala. "Without them, it would be hard to continue treatment."
Platinum prices have rallied on expectations of a fourth consecutive year of market deficits, driven by constrained mine supply, robust investment demand and dwindling inventories as the metal replaces palladium in automotive applications.
DRUGMAKERS SEEK PRICE REVISION
Drugmakers are unable to pass on higher costs as the government caps the prices of the medicines, though they have sought an increase of roughly 50% in the price caps.
India's pharmaceuticals department did not respond to requests for comment.
Some manufacturers have cut production.
The struggle to find platinum-based raw material has prompted Naprod Life Sciences to temporarily halt output of cisplatin and carboplatin, for example.
"The shortage is primarily driven by a steep increase in platinum prices," said company director Mohan Jain, adding that prices over the past year have jumped to 5,000 rupees ($52.30) for one gram from about 2,000 rupees.
Venus Remedies, which supplies to government hospitals, said it has been absorbing losses but is now cautious about taking on new contracts.
"If those caps are not adjusted in line with rising costs, the supply chain comes under pressure," said Executive Director Saransh Chaudhary. "Companies cannot absorb the full increase, so patients ultimately bear the impact and shortages persist."
The other drugmakers did not respond to Reuters requests for comment.
There are few alternatives to the platinum-based cancer drugs, and substitutes can be less effective or more toxic, said oncologist Venkateshwar Rao at Omega Hospital in the southern state of Andhra Pradesh.
($1=95.6000 rupees)
(Reporting by Rishika Sadam; Editing by Dhanya Skariachan and Clarence Fernandez)
(([email protected];))
Adds sector context, analyst comment in paragraphs 2 and 4
By Kashish Tandon
May 22 (Reuters) - Sun Pharmaceutical Industries' SUN.NS fourth-quarter profit edged past estimates, helped by robust demand for its specialty drugs, although increasing cost pressures squeezed margins and sent shares lower on Friday.
The drugmaker's shares fell as much as 3.1% after results before closing 2.5% lower for the day.
Growing costs, especially in the research and development category, as per analysts, pushed up overall expenses 16% to 115.19 billion rupees.
This ate into core margins, which contracted to 27.1% from 28.7% last year. Shrikant Akolkar, a pharma analyst with Nuvama Institutional Equities, called the cost pressure and margins "disappointing".
Consolidated net profit for the March quarter rose 26.2% to 27.14 billion rupees ($283 million), edging past analysts' estimate of 27.12 billion rupees, according to LSEG data.
The drugmaker's push towards boosting its specialty therapies such as dermatology, oncology and obesity helped its bottomline and also allowed it to outperform rivals Dr Reddy's REDY.NS and Cipla CIPL.NS, which missed March-quarter estimates.
Revenue in the specialty drugs segment rose 20% to $354 million - accounting for nearly a quarter of total sales - helped by 14.8% growth in India, its biggest market. U.S. sales fell 1.1%.
The earnings come weeks after Sun Pharma struck its most ambitious deal yet: an $11.75 billion all-cash offer for U.S.-based Organon & Co OGN.N, the largest acquisition ever by an Indian pharmaceutical company.
($1 = 95.9125 Indian rupees)
(Reporting by Rishika Sadam and Kashish Tandon, writing by Chandini Monnappa; Editing by Nivedita Bhattacharjee and Janane Venkatraman)
(([email protected];))
Adds sector context, analyst comment in paragraphs 2 and 4
By Kashish Tandon
May 22 (Reuters) - Sun Pharmaceutical Industries' SUN.NS fourth-quarter profit edged past estimates, helped by robust demand for its specialty drugs, although increasing cost pressures squeezed margins and sent shares lower on Friday.
The drugmaker's shares fell as much as 3.1% after results before closing 2.5% lower for the day.
Growing costs, especially in the research and development category, as per analysts, pushed up overall expenses 16% to 115.19 billion rupees.
This ate into core margins, which contracted to 27.1% from 28.7% last year. Shrikant Akolkar, a pharma analyst with Nuvama Institutional Equities, called the cost pressure and margins "disappointing".
Consolidated net profit for the March quarter rose 26.2% to 27.14 billion rupees ($283 million), edging past analysts' estimate of 27.12 billion rupees, according to LSEG data.
The drugmaker's push towards boosting its specialty therapies such as dermatology, oncology and obesity helped its bottomline and also allowed it to outperform rivals Dr Reddy's REDY.NS and Cipla CIPL.NS, which missed March-quarter estimates.
Revenue in the specialty drugs segment rose 20% to $354 million - accounting for nearly a quarter of total sales - helped by 14.8% growth in India, its biggest market. U.S. sales fell 1.1%.
The earnings come weeks after Sun Pharma struck its most ambitious deal yet: an $11.75 billion all-cash offer for U.S.-based Organon & Co OGN.N, the largest acquisition ever by an Indian pharmaceutical company.
($1 = 95.9125 Indian rupees)
(Reporting by Rishika Sadam and Kashish Tandon, writing by Chandini Monnappa; Editing by Nivedita Bhattacharjee and Janane Venkatraman)
(([email protected];))
** Shares of Cipla CIPL.NS gain ~6% so far this week, set for best week since July 2023
** Stock set to gain for sixth straight week
** Earlier this week, the drugmaker reported a weaker-than-expected fourth-quarter profit as sharp weakness in its U.S. business and higher costs outweighed strong domestic demand
** Analysts at Ambit Capital had said revenue and profitability have largely bottomed out, and gradual sequential improvement should be visible through FY27
** YTD, CIPL down ~5% vs ~9% fall in Nifty 50 index .NSEI
(Reporting by Vijay Malkar)
(([email protected];))
** Shares of Cipla CIPL.NS gain ~6% so far this week, set for best week since July 2023
** Stock set to gain for sixth straight week
** Earlier this week, the drugmaker reported a weaker-than-expected fourth-quarter profit as sharp weakness in its U.S. business and higher costs outweighed strong domestic demand
** Analysts at Ambit Capital had said revenue and profitability have largely bottomed out, and gradual sequential improvement should be visible through FY27
** YTD, CIPL down ~5% vs ~9% fall in Nifty 50 index .NSEI
(Reporting by Vijay Malkar)
(([email protected];))
** Drugmaker Cipla CIPL.NS shares rise 7.7% to 1,362 rupees after reporting Q4 results
** Co reports Q4 consolidated net profit of 5.55 bln rupees ($57.98 million), compared to avg analysts' estimate of 7.05 bln rupees, according to data compiled by LSEG
** Posts total revenue from operations of 65.41 billion rupees, below estimate of 67.49 billion rupees
** "While Cipla's 4QFY26 EBITDA margin performance was weaker than street/our expectations, the silver lining was the meaningful beat in gross margin," analysts at Emkay Capital say
** Analysts at Ambit Capital believe revenue and profitability have largely bottomed out, and gradual sequential improvement should be visible through FY27
** Jefferies analysts say Cipla is likely to face near-term earnings pressure, as new launches in FY27 may not offset the sales loss from two major products, generic Revlimid and Lanreotide
** YTD, stock down 12.2%
($1 = 95.7200 Indian rupees)
(Reporting by Abhinav Parmar in Bengaluru)
(([email protected];))
** Drugmaker Cipla CIPL.NS shares rise 7.7% to 1,362 rupees after reporting Q4 results
** Co reports Q4 consolidated net profit of 5.55 bln rupees ($57.98 million), compared to avg analysts' estimate of 7.05 bln rupees, according to data compiled by LSEG
** Posts total revenue from operations of 65.41 billion rupees, below estimate of 67.49 billion rupees
** "While Cipla's 4QFY26 EBITDA margin performance was weaker than street/our expectations, the silver lining was the meaningful beat in gross margin," analysts at Emkay Capital say
** Analysts at Ambit Capital believe revenue and profitability have largely bottomed out, and gradual sequential improvement should be visible through FY27
** Jefferies analysts say Cipla is likely to face near-term earnings pressure, as new launches in FY27 may not offset the sales loss from two major products, generic Revlimid and Lanreotide
** YTD, stock down 12.2%
($1 = 95.7200 Indian rupees)
(Reporting by Abhinav Parmar in Bengaluru)
(([email protected];))
Adds details from paragraph 3 onwards; share moves in last paragraph
May 13 (Reuters) - Cipla CIPL.NS, India's third-largest drugmaker by revenue, reported a weaker-than-expected fourth-quarter profit on Wednesday, as sharp weakness in its U.S. business and higher costs outweighed strong domestic demand.
The drugmaker's consolidated net profit fell 54.6% on-year to 5.55 billion rupees ($58 million) in the quarter ended March 31, missing analysts' average estimate of 7.05 billion rupees, according to data compiled by LSEG.
Total revenue from operations fell 2.8% to 65.41 billion rupees, below the average expectations of 67.49 billion rupees, hurt by a sales decline in its key North America market.
Revenue from India, Cipla's biggest market by sales, jumped 15% to 30.07 billion rupees, while revenue from North America fell 26% to 14.14 billion rupees.
The Indian and North American markets account for roughly three-fourths of the drugmaker's total sales.
Total expenses rose nearly 8.5% to 18.82 billion rupees, driven by higher costs.
The company also recorded an impairment charge of about 420.2 million rupees on its associates, adding to cost pressures.
Analysts at Jefferies said in a pre-earnings note that they expect U.S. sales to decline in the near term due to erosion in key products, with margins likely to remain under pressure until new launches scale up.
The company declared a dividend of 13 rupees per share.
Rival Dr Reddy's REDY.NS reported a sharp drop in quarterly profit on Tuesday, hurt by an impairment charge linked to its discontinued cancer therapy program.
However, Cipla shares were trading 4.23% higher in the afternoon. The stock has fallen about 14.3% so far this year.
($1 = 95.6700 Indian rupees)
(Reporting by Bipasha Dey in Bengaluru; Editing by Rashmi Aich and Mrigank Dhaniwala)
(([email protected];))
Adds details from paragraph 3 onwards; share moves in last paragraph
May 13 (Reuters) - Cipla CIPL.NS, India's third-largest drugmaker by revenue, reported a weaker-than-expected fourth-quarter profit on Wednesday, as sharp weakness in its U.S. business and higher costs outweighed strong domestic demand.
The drugmaker's consolidated net profit fell 54.6% on-year to 5.55 billion rupees ($58 million) in the quarter ended March 31, missing analysts' average estimate of 7.05 billion rupees, according to data compiled by LSEG.
Total revenue from operations fell 2.8% to 65.41 billion rupees, below the average expectations of 67.49 billion rupees, hurt by a sales decline in its key North America market.
Revenue from India, Cipla's biggest market by sales, jumped 15% to 30.07 billion rupees, while revenue from North America fell 26% to 14.14 billion rupees.
The Indian and North American markets account for roughly three-fourths of the drugmaker's total sales.
Total expenses rose nearly 8.5% to 18.82 billion rupees, driven by higher costs.
The company also recorded an impairment charge of about 420.2 million rupees on its associates, adding to cost pressures.
Analysts at Jefferies said in a pre-earnings note that they expect U.S. sales to decline in the near term due to erosion in key products, with margins likely to remain under pressure until new launches scale up.
The company declared a dividend of 13 rupees per share.
Rival Dr Reddy's REDY.NS reported a sharp drop in quarterly profit on Tuesday, hurt by an impairment charge linked to its discontinued cancer therapy program.
However, Cipla shares were trading 4.23% higher in the afternoon. The stock has fallen about 14.3% so far this year.
($1 = 95.6700 Indian rupees)
(Reporting by Bipasha Dey in Bengaluru; Editing by Rashmi Aich and Mrigank Dhaniwala)
(([email protected];))
Changes dateline, updates paragraph 1, adds Amgen's investment
May 4 (Reuters) - Global drugmakers have been ramping up U.S. manufacturing and stockpiling inventory as the Trump administration moves to impose 100% tariffs on branded drugs unless companies cut prices or make medicines domestically.
Although enforcement is delayed for companies investing in U.S. manufacturing, the policy has already prompted fast-tracked projects, price cuts and direct-to-consumer sales.
Pfizer and AstraZeneca secured multi-year tariff exemptions through pricing deals and commitments to the new TrumpRx.gov platform. Eli Lilly, Johnson & Johnson and Merck have pledged billions to expand U.S. operations to avoid penalties.
Here's what drugmakers are doing to mitigate supply-chain risks and reassure investors:
Pfizer PFE.N
Pfizer reached a deal with President Donald Trump on September 30 to invest $70 billion in research and development and domestic manufacturing, and received a three-year grace period exempting its products from the pharmaceutical-targeted tariffs.
GSK GSK.L
The London-based drugmaker plans to invest $30 billion in U.S. research and development and supply chain infrastructure over five years.
Eli Lilly LLY.N
U.S. President Donald Trump said in January that Eli Lilly plans to build six plants in the United States.
Lilly said last year that it planned to spend at least $27 billion to build four U.S. plants to expand production and bolster medical supply chains. The company has since announced details on three plants, in Alabama, Virginia and Texas.
Lilly in January said it will build a $3.5 billion pharmaceutical manufacturing facility in Pennsylvania, its fourth new site, in an effort to expand U.S. production and bolster medical supply chains.
Johnson & Johnson JNJ.N
The drugmaker plans to raise U.S. investments by 25%, totaling $55 billion, over the next four years. It plans to build four plants, including one at Wilson, North Carolina, and another at Tokyo-based Fujifilm Biotechnologies' manufacturing site in Holly Springs, North Carolina, over the next 10 years.
The company said in February it would invest more than $1 billion to build a new cell therapy facility in Pennsylvania, part of its larger plans announced last year to scale up U.S. manufacturing.
Roche ROG.S
The Swiss drugmaker said in April last year it would invest $50 billion in the U.S. over the next five years.
A month later, it announced an additional $550 million investment to expand its Indianapolis diagnostics manufacturing hub. The expansion will span Indiana, Pennsylvania, Massachusetts, and California, creating more than 12,000 jobs.
In January, Roche said it will more than double its investment in its drug manufacturing facility in Holly Springs, North Carolina, to about $2 billion, up from the over $700 million announced in May 2025.
AstraZeneca AZN.L
The Anglo-Swedish drugmaker will invest $50 billion on U.S. manufacturing by 2030. The investment will fund a new drug substance facility in Virginia, its largest single-site global investment, alongside expansions in Maryland, Massachusetts, California, Indiana and Texas.
It has already started technology transfers and is managing inventory in 2025 to minimize any tariff hit. Company executives have said the impact would be "very short-lived."
Novartis NOVN.S
The Swiss drugmaker plans to spend $23 billion to build and expand 10 facilities in the U.S. over the next five years. This includes building six new manufacturing plants and expanding its San Diego research and development site, which is expected to create more than 1,000 jobs.
Sanofi SASY.PA
The French drugmaker plans to invest at least $20 billion in the U.S. through 2030 to boost manufacturing and research. Sanofi plans to expand its U.S. manufacturing capacity through direct investments in the company's sites and partnerships with other domestic manufacturers.
Chief Financial Officer François Roger said in July the potential tariffs are expected to have a limited impact in 2025, as the company already has inventory in place in the U.S.
Biogen BIIB.O
The U.S. drugmaker will invest $2 billion more in its existing manufacturing plants in North Carolina, adding capacity for gene-targeting therapies and automation. The company has seven factories in the state, with an eighth set to begin operations in late 2025.
Merck MRK.N
The U.S. drugmaker has begun building a $3 billion pharmaceutical manufacturing plant in Virginia as part of its over $70 billion investment to expand domestic manufacturing and research and development.
It will also invest $1 billion in a new Delaware plant to make biologics and cancer drug Keytruda, to boost U.S. production and potentially create over 4,500 jobs. It also opened a $1 billion facility at its North Carolina site in March.
Merck's animal health unit will invest $895 million to expand its Kansas manufacturing and R&D site, part of a broader $9 billion U.S. investment through 2028.
CEO Robert Davis in July flagged minimal impact from potential tariffs in 2025, and that the company remained well-positioned due to inventory management and moving of manufacturing to the U.S.
Amgen AMGN.O
The U.S.-based biopharma firm plans to invest $900 million to expand its Ohio manufacturing facility, bringing total investment in the state to $1.4 billion and adding 750 jobs. In December, the company committed $1 billion to build a second facility in Holly Springs, North Carolina.
Amgen said in September it is investing more than $600 million to build a new research and development center at its headquarters in Thousand Oaks, California.
The drugmaker announced it will invest $650 million to expand drug manufacturing at its facility in Juncos, Puerto Rico, a move expected to create nearly 750 jobs.
Amgen said it would invest an additional $300 million in its U.S. manufacturing network, expanding its biologics facility in Puerto Rico and support hundreds of construction jobs.
Novo Nordisk NOVOb.CO
The Danish pharmaceutical company said in August its strong U.S. manufacturing footprint positions it well for tariff challenges, describing itself as "very U.S.-centric and U.S.-focused".
AbbVie ABBV.N
U.S. drugmaker AbbVie ABBV.N said in January it has committed $100 billion over the next decade to U.S.-based research and development as part of its three-year deal with the Trump administration to reduce drug prices.
It has 11 manufacturing sites in the U.S. and has said it is "fairly insulated" from any tariff impact this year, given inventory management actions.
The company said in February that it plans to invest $380 million to build two manufacturing facilities at its current North Chicago, Illinois, campus, to support the production of its neuroscience and obesity medications.
Gilead Sciences GILD.O
Earlier this year, the drugmaker announced $11 billion in new planned investment in the U.S. to add to its domestic manufacturing and research heft, taking its total pledged investment to $32 billion.
Gilead said in September that it started work on a pharmaceutical development and manufacturing hub at its headquarters in Foster City, California, in addition to which, it is currently developing two other sites.
Cipla CIPL.NS
The Indian drugmaker is expanding its U.S. manufacturing footprint by investing in capacity expansion for complex respiratory products at its advanced facilities in Fall River, Massachusetts, and Central Islip, New York.
CSL CSL.AX
Australia's CSL said in November it would invest $1.5 billion in the U.S. to manufacture plasma-derived therapies, expanding its footprint in the country over the next five years.
In March, the company announced the expansion of its plasma therapy manufacturing facility in Kankakee, Illinois, which is expected to be operational by 2031.
(Reporting by Siddhi Mahatole, Kamal Choudhury, Puyaan Singh, Sneha S K and Sahil Pandey in Bengaluru; Editing by Tasim Zahid, Sahal Muhammed, Shinjini Ganguli and Maju Samuel)
(([email protected];))
Changes dateline, updates paragraph 1, adds Amgen's investment
May 4 (Reuters) - Global drugmakers have been ramping up U.S. manufacturing and stockpiling inventory as the Trump administration moves to impose 100% tariffs on branded drugs unless companies cut prices or make medicines domestically.
Although enforcement is delayed for companies investing in U.S. manufacturing, the policy has already prompted fast-tracked projects, price cuts and direct-to-consumer sales.
Pfizer and AstraZeneca secured multi-year tariff exemptions through pricing deals and commitments to the new TrumpRx.gov platform. Eli Lilly, Johnson & Johnson and Merck have pledged billions to expand U.S. operations to avoid penalties.
Here's what drugmakers are doing to mitigate supply-chain risks and reassure investors:
Pfizer PFE.N
Pfizer reached a deal with President Donald Trump on September 30 to invest $70 billion in research and development and domestic manufacturing, and received a three-year grace period exempting its products from the pharmaceutical-targeted tariffs.
GSK GSK.L
The London-based drugmaker plans to invest $30 billion in U.S. research and development and supply chain infrastructure over five years.
Eli Lilly LLY.N
U.S. President Donald Trump said in January that Eli Lilly plans to build six plants in the United States.
Lilly said last year that it planned to spend at least $27 billion to build four U.S. plants to expand production and bolster medical supply chains. The company has since announced details on three plants, in Alabama, Virginia and Texas.
Lilly in January said it will build a $3.5 billion pharmaceutical manufacturing facility in Pennsylvania, its fourth new site, in an effort to expand U.S. production and bolster medical supply chains.
Johnson & Johnson JNJ.N
The drugmaker plans to raise U.S. investments by 25%, totaling $55 billion, over the next four years. It plans to build four plants, including one at Wilson, North Carolina, and another at Tokyo-based Fujifilm Biotechnologies' manufacturing site in Holly Springs, North Carolina, over the next 10 years.
The company said in February it would invest more than $1 billion to build a new cell therapy facility in Pennsylvania, part of its larger plans announced last year to scale up U.S. manufacturing.
Roche ROG.S
The Swiss drugmaker said in April last year it would invest $50 billion in the U.S. over the next five years.
A month later, it announced an additional $550 million investment to expand its Indianapolis diagnostics manufacturing hub. The expansion will span Indiana, Pennsylvania, Massachusetts, and California, creating more than 12,000 jobs.
In January, Roche said it will more than double its investment in its drug manufacturing facility in Holly Springs, North Carolina, to about $2 billion, up from the over $700 million announced in May 2025.
AstraZeneca AZN.L
The Anglo-Swedish drugmaker will invest $50 billion on U.S. manufacturing by 2030. The investment will fund a new drug substance facility in Virginia, its largest single-site global investment, alongside expansions in Maryland, Massachusetts, California, Indiana and Texas.
It has already started technology transfers and is managing inventory in 2025 to minimize any tariff hit. Company executives have said the impact would be "very short-lived."
Novartis NOVN.S
The Swiss drugmaker plans to spend $23 billion to build and expand 10 facilities in the U.S. over the next five years. This includes building six new manufacturing plants and expanding its San Diego research and development site, which is expected to create more than 1,000 jobs.
Sanofi SASY.PA
The French drugmaker plans to invest at least $20 billion in the U.S. through 2030 to boost manufacturing and research. Sanofi plans to expand its U.S. manufacturing capacity through direct investments in the company's sites and partnerships with other domestic manufacturers.
Chief Financial Officer François Roger said in July the potential tariffs are expected to have a limited impact in 2025, as the company already has inventory in place in the U.S.
Biogen BIIB.O
The U.S. drugmaker will invest $2 billion more in its existing manufacturing plants in North Carolina, adding capacity for gene-targeting therapies and automation. The company has seven factories in the state, with an eighth set to begin operations in late 2025.
Merck MRK.N
The U.S. drugmaker has begun building a $3 billion pharmaceutical manufacturing plant in Virginia as part of its over $70 billion investment to expand domestic manufacturing and research and development.
It will also invest $1 billion in a new Delaware plant to make biologics and cancer drug Keytruda, to boost U.S. production and potentially create over 4,500 jobs. It also opened a $1 billion facility at its North Carolina site in March.
Merck's animal health unit will invest $895 million to expand its Kansas manufacturing and R&D site, part of a broader $9 billion U.S. investment through 2028.
CEO Robert Davis in July flagged minimal impact from potential tariffs in 2025, and that the company remained well-positioned due to inventory management and moving of manufacturing to the U.S.
Amgen AMGN.O
The U.S.-based biopharma firm plans to invest $900 million to expand its Ohio manufacturing facility, bringing total investment in the state to $1.4 billion and adding 750 jobs. In December, the company committed $1 billion to build a second facility in Holly Springs, North Carolina.
Amgen said in September it is investing more than $600 million to build a new research and development center at its headquarters in Thousand Oaks, California.
The drugmaker announced it will invest $650 million to expand drug manufacturing at its facility in Juncos, Puerto Rico, a move expected to create nearly 750 jobs.
Amgen said it would invest an additional $300 million in its U.S. manufacturing network, expanding its biologics facility in Puerto Rico and support hundreds of construction jobs.
Novo Nordisk NOVOb.CO
The Danish pharmaceutical company said in August its strong U.S. manufacturing footprint positions it well for tariff challenges, describing itself as "very U.S.-centric and U.S.-focused".
AbbVie ABBV.N
U.S. drugmaker AbbVie ABBV.N said in January it has committed $100 billion over the next decade to U.S.-based research and development as part of its three-year deal with the Trump administration to reduce drug prices.
It has 11 manufacturing sites in the U.S. and has said it is "fairly insulated" from any tariff impact this year, given inventory management actions.
The company said in February that it plans to invest $380 million to build two manufacturing facilities at its current North Chicago, Illinois, campus, to support the production of its neuroscience and obesity medications.
Gilead Sciences GILD.O
Earlier this year, the drugmaker announced $11 billion in new planned investment in the U.S. to add to its domestic manufacturing and research heft, taking its total pledged investment to $32 billion.
Gilead said in September that it started work on a pharmaceutical development and manufacturing hub at its headquarters in Foster City, California, in addition to which, it is currently developing two other sites.
Cipla CIPL.NS
The Indian drugmaker is expanding its U.S. manufacturing footprint by investing in capacity expansion for complex respiratory products at its advanced facilities in Fall River, Massachusetts, and Central Islip, New York.
CSL CSL.AX
Australia's CSL said in November it would invest $1.5 billion in the U.S. to manufacture plasma-derived therapies, expanding its footprint in the country over the next five years.
In March, the company announced the expansion of its plasma therapy manufacturing facility in Kankakee, Illinois, which is expected to be operational by 2031.
(Reporting by Siddhi Mahatole, Kamal Choudhury, Puyaan Singh, Sneha S K and Sahil Pandey in Bengaluru; Editing by Tasim Zahid, Sahal Muhammed, Shinjini Ganguli and Maju Samuel)
(([email protected];))
Adds background on trial in paragraph 2, revenue in paragraph 3, and analyst quote in paragraph 6
April 28 (Reuters) - Pfizer PFE.N said on Tuesday it has settled patent disputes with three generic drugmakers over its blockbuster heart drug Vyndamax, effectively extending its patent protection until 2031 and delaying cheaper copies from entering the market.
The deals resolve patent infringement lawsuits against Dexcel Pharma, Hikma Pharmaceuticals HIK.L and Cipla CIPL.NS in Delaware federal court over Pfizer's oral drug Vyndamax. A trial over the patent had started this week.
Pfizer sold nearly $6.4 billion of Vyndamax and related drugs, which treat a serious heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM), in 2025.
The settlements extend U.S. patent protection for Vyndamax until June 1, 2031, subject to other pending litigation.
The company had previously expected a sharp drop in U.S. revenue for the drug in 2029, but now expects sales to hold relatively steady from 2028 through mid-2031.
JP Morgan analyst Chris Schott said in a research note that in light of the drugmaker's other impending patent expirations, which include some of its other top selling drugs like blood thinner Eliquis and cancer drug Ibrance, the settlement "should smooth out the company’s late-2020s earnings profile and give Pfizer additional time for pipeline development."
Shares of Pfizer were up slightly in late morning trading.
(Reporting by Kamal Choudhury in Bengaluru and MIchael Erman in New Jersey; Editing by Chizu Nomiyama)
(([email protected];))
Adds background on trial in paragraph 2, revenue in paragraph 3, and analyst quote in paragraph 6
April 28 (Reuters) - Pfizer PFE.N said on Tuesday it has settled patent disputes with three generic drugmakers over its blockbuster heart drug Vyndamax, effectively extending its patent protection until 2031 and delaying cheaper copies from entering the market.
The deals resolve patent infringement lawsuits against Dexcel Pharma, Hikma Pharmaceuticals HIK.L and Cipla CIPL.NS in Delaware federal court over Pfizer's oral drug Vyndamax. A trial over the patent had started this week.
Pfizer sold nearly $6.4 billion of Vyndamax and related drugs, which treat a serious heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM), in 2025.
The settlements extend U.S. patent protection for Vyndamax until June 1, 2031, subject to other pending litigation.
The company had previously expected a sharp drop in U.S. revenue for the drug in 2029, but now expects sales to hold relatively steady from 2028 through mid-2031.
JP Morgan analyst Chris Schott said in a research note that in light of the drugmaker's other impending patent expirations, which include some of its other top selling drugs like blood thinner Eliquis and cancer drug Ibrance, the settlement "should smooth out the company’s late-2020s earnings profile and give Pfizer additional time for pipeline development."
Shares of Pfizer were up slightly in late morning trading.
(Reporting by Kamal Choudhury in Bengaluru and MIchael Erman in New Jersey; Editing by Chizu Nomiyama)
(([email protected];))
** Shares of Indian pharma company Cohance Lifesciences COHA.NS surge 20% to 432.10 rupees in biggest pct gain since June 2020
** Former Cipla CIPL.NS MD and global CEO, Umang Vohra, appointed CEO of Cohance on Monday
** Vohra led Cipla for more than 9 years; CIPL share price moved up more than 1.5x in the period
** 13.7 mln shares change hands by 11:32 am, more than 4x the 30-day avg
** COHA rated "buy" on avg by 8 analysts; median PT 392 rupees - LSEG data
** YTD, COHA down 18.2%
(Reporting by Abhirami G in Bengaluru)
** Shares of Indian pharma company Cohance Lifesciences COHA.NS surge 20% to 432.10 rupees in biggest pct gain since June 2020
** Former Cipla CIPL.NS MD and global CEO, Umang Vohra, appointed CEO of Cohance on Monday
** Vohra led Cipla for more than 9 years; CIPL share price moved up more than 1.5x in the period
** 13.7 mln shares change hands by 11:32 am, more than 4x the 30-day avg
** COHA rated "buy" on avg by 8 analysts; median PT 392 rupees - LSEG data
** YTD, COHA down 18.2%
(Reporting by Abhirami G in Bengaluru)
** Shares of India's Cipla CIPL.NS on track for 4.99% weekly gain, eyes best week since July 2025
** Stock down 0.42% at 1,300.5 rupees on the day vs Nifty 50 .NSEI drop of 1.42%
** Drugmaker received U.S. FDA approval for its Abbreviated New Drug Application for the generic equivalent of inhaler Ventolin HFA
** Motilal Oswal("neutral"; TP:1,306 rupees)says g-Ventolin to aid growth and strengthen respiratory portfolio; sees 6–8% earnings CAGR over FY26–28
** Citi ("buy", TP: 1,530 rupees) says approval is key to boosting confidence in pipeline; expects product to contribute$50-70 million in revenue
** CIPL rated "hold" on avg by 37 analysts; median PT 1,438 rupees
** YTD stock down 13.59% vs Nifty 50 down 8.86%
(Reporting by Devika Nair in Bengaluru)
(([email protected];))
** Shares of India's Cipla CIPL.NS on track for 4.99% weekly gain, eyes best week since July 2025
** Stock down 0.42% at 1,300.5 rupees on the day vs Nifty 50 .NSEI drop of 1.42%
** Drugmaker received U.S. FDA approval for its Abbreviated New Drug Application for the generic equivalent of inhaler Ventolin HFA
** Motilal Oswal("neutral"; TP:1,306 rupees)says g-Ventolin to aid growth and strengthen respiratory portfolio; sees 6–8% earnings CAGR over FY26–28
** Citi ("buy", TP: 1,530 rupees) says approval is key to boosting confidence in pipeline; expects product to contribute$50-70 million in revenue
** CIPL rated "hold" on avg by 37 analysts; median PT 1,438 rupees
** YTD stock down 13.59% vs Nifty 50 down 8.86%
(Reporting by Devika Nair in Bengaluru)
(([email protected];))
April 23 (Reuters) - Cipla Ltd CIPL.NS:
CIPLA RECEIVES U.S. FDA APPROVAL FOR FIRST AB-RATED GENERIC OF VENTOLIN® HFA
Source text: ID:nPn7l5ygca
Further company coverage: CIPL.NS
(([email protected];;))
April 23 (Reuters) - Cipla Ltd CIPL.NS:
CIPLA RECEIVES U.S. FDA APPROVAL FOR FIRST AB-RATED GENERIC OF VENTOLIN® HFA
Source text: ID:nPn7l5ygca
Further company coverage: CIPL.NS
(([email protected];;))
April 17 (Reuters) - Cipla Ltd CIPL.NS:
CIPLA - USFDA INSPECTION AT COMPANY'S MANUFACTURING FACILITY IN GOA, INDIA
CIPLA - USFDA INSPECTION AT COMPANY'S MANUFACTURING FACILITY IN GOA, INDIA
CIPLA - USFDA CONDUCTS INSPECTION AT CIPLA GOA FACILITY FROM APRIL 6-17, 2026
CIPLA - RECEIVES TWO INSPECTIONAL OBSERVATIONS IN FORM 483
Source text: ID:nBSE5VLYW0
Further company coverage: CIPL.NS
(([email protected];;))
April 17 (Reuters) - Cipla Ltd CIPL.NS:
CIPLA - USFDA INSPECTION AT COMPANY'S MANUFACTURING FACILITY IN GOA, INDIA
CIPLA - USFDA INSPECTION AT COMPANY'S MANUFACTURING FACILITY IN GOA, INDIA
CIPLA - USFDA CONDUCTS INSPECTION AT CIPLA GOA FACILITY FROM APRIL 6-17, 2026
CIPLA - RECEIVES TWO INSPECTIONAL OBSERVATIONS IN FORM 483
Source text: ID:nBSE5VLYW0
Further company coverage: CIPL.NS
(([email protected];;))
The author is a Reuters Breakingviews columnist. The opinions expressed are his own.
By Robert Cyran
NEW YORK, April 6 (Reuters Breakingviews) - The spice must flow. So goes the dictum of science-fiction universe Dune, dependent on a mysterious substance for space travel. In the real world, Taiwan’s semiconductor factories are of similarly existential importance. Shortages of both liquefied natural gas and helium threaten production. If they need reassurance, chipmakers can look to a very literal case of keeping the spice flowing from the recent past.
In 2005, a nasty avian influenza strain threatened the world. Drugmaker Roche’s ROPC.S Tamiflu was the best choice for fighting symptoms. The problem was, the United States had stockpiled millions of doses. To fill other nations’ orders, then-Roche boss Franz Humer needed to secure a compound found in an Asian pantry staple: star anise. The spice was the primary source of shikimic acid, a chemical necessary for manufacturing Tamiflu.
There was no burst of supply that could sate this new demand. Demand for the spice rocketed, and the price of shikimic acid rose ten-fold in a month. Yusuf Hamied, chairman of Indian drugmaker Cipla CIPL.NS, complained that his rival had cornered the market. Grumbling cooks, too, were largely priced out. But Roche produced its treatment.
Now consider cutting-edge chips. Taiwan Semiconductor Manufacturing 2330.TW is the essential silicon manufacturer for Nvidia NVDA.O and its peers. To keep factories humming, the company needs power and raw materials. Conflict in the Gulf threatens both.
LNG accounted for nearly half of Taiwan’s electricity generation last year. One-third of the island’s supply came from Qatar, which is now largely shut down. But ships from elsewhere are still sailing, and can be rerouted if a higher bidder jumps in. Taiwan can afford to do so, and supplies are sufficient: Asian prices are still well below 2022’s heights. Furthermore, the nation’s total imports last year equate to about two months’ worth of U.S. exports, and Washington would surely react if chip supplies were really threatened.
Then there are raw materials, particularly helium. Semiconductor makers account for 23% of global demand, according to Bank of America, while around 27% of supply has been taken offline amid the fighting. Like the chefs outbid by Roche, good luck to welders or balloon-pumping party planners in competing with $1.8 trillion titan TSMC for what's left.
Star anise also shows that markets eventually find more elegant solutions. Roche now produces star anise’s active ingredient via cheap, plentiful bacterial fermentation. Taiwan will undoubtedly source different forms of power, while surprising new sources of helium will probably emerge. Odds are, silicon will continue to flow.
Follow Robert Cyran on Bluesky.
CONTEXT NEWS
U.S. and Israeli attacks on Iran that started on February 28 have led to the effective closure of the Strait of Hormuz, which normally carries about 20% of the world's oil and refined products.
The Strait also carries large amounts of helium, necessary for semiconductor manufacturing. Qatar produces nearly a third of the world’s supply, according to Bank of America analysts.
Asian LNG spot prices still well below 2022's peak https://www.reuters.com/graphics/BRV-BRV/BRV-BRV/zdpxgqmgjvx/chart.png
(Editing by Jonathan Guilford; Production by Pranav Kiran)
((For previous columns by the author, Reuters customers can click on CYRAN/[email protected]; Reuters Messaging: [email protected]))
The author is a Reuters Breakingviews columnist. The opinions expressed are his own.
By Robert Cyran
NEW YORK, April 6 (Reuters Breakingviews) - The spice must flow. So goes the dictum of science-fiction universe Dune, dependent on a mysterious substance for space travel. In the real world, Taiwan’s semiconductor factories are of similarly existential importance. Shortages of both liquefied natural gas and helium threaten production. If they need reassurance, chipmakers can look to a very literal case of keeping the spice flowing from the recent past.
In 2005, a nasty avian influenza strain threatened the world. Drugmaker Roche’s ROPC.S Tamiflu was the best choice for fighting symptoms. The problem was, the United States had stockpiled millions of doses. To fill other nations’ orders, then-Roche boss Franz Humer needed to secure a compound found in an Asian pantry staple: star anise. The spice was the primary source of shikimic acid, a chemical necessary for manufacturing Tamiflu.
There was no burst of supply that could sate this new demand. Demand for the spice rocketed, and the price of shikimic acid rose ten-fold in a month. Yusuf Hamied, chairman of Indian drugmaker Cipla CIPL.NS, complained that his rival had cornered the market. Grumbling cooks, too, were largely priced out. But Roche produced its treatment.
Now consider cutting-edge chips. Taiwan Semiconductor Manufacturing 2330.TW is the essential silicon manufacturer for Nvidia NVDA.O and its peers. To keep factories humming, the company needs power and raw materials. Conflict in the Gulf threatens both.
LNG accounted for nearly half of Taiwan’s electricity generation last year. One-third of the island’s supply came from Qatar, which is now largely shut down. But ships from elsewhere are still sailing, and can be rerouted if a higher bidder jumps in. Taiwan can afford to do so, and supplies are sufficient: Asian prices are still well below 2022’s heights. Furthermore, the nation’s total imports last year equate to about two months’ worth of U.S. exports, and Washington would surely react if chip supplies were really threatened.
Then there are raw materials, particularly helium. Semiconductor makers account for 23% of global demand, according to Bank of America, while around 27% of supply has been taken offline amid the fighting. Like the chefs outbid by Roche, good luck to welders or balloon-pumping party planners in competing with $1.8 trillion titan TSMC for what's left.
Star anise also shows that markets eventually find more elegant solutions. Roche now produces star anise’s active ingredient via cheap, plentiful bacterial fermentation. Taiwan will undoubtedly source different forms of power, while surprising new sources of helium will probably emerge. Odds are, silicon will continue to flow.
Follow Robert Cyran on Bluesky.
CONTEXT NEWS
U.S. and Israeli attacks on Iran that started on February 28 have led to the effective closure of the Strait of Hormuz, which normally carries about 20% of the world's oil and refined products.
The Strait also carries large amounts of helium, necessary for semiconductor manufacturing. Qatar produces nearly a third of the world’s supply, according to Bank of America analysts.
Asian LNG spot prices still well below 2022's peak https://www.reuters.com/graphics/BRV-BRV/BRV-BRV/zdpxgqmgjvx/chart.png
(Editing by Jonathan Guilford; Production by Pranav Kiran)
((For previous columns by the author, Reuters customers can click on CYRAN/[email protected]; Reuters Messaging: [email protected]))
April 2 (Reuters) - Cipla Ltd CIPL.NS:
CIPLA EXPANDS U.S. RESPIRATORY PORTFOLIO WITH APPROVAL OF NINTEDANIB CAPSULES (100MG & 150MG) FOR IDIOPATHIC PULMONARY FIBROSIS
Source text: ID:nPn6WdvDya
Further company coverage: CIPL.NS
(([email protected];))
April 2 (Reuters) - Cipla Ltd CIPL.NS:
CIPLA EXPANDS U.S. RESPIRATORY PORTFOLIO WITH APPROVAL OF NINTEDANIB CAPSULES (100MG & 150MG) FOR IDIOPATHIC PULMONARY FIBROSIS
Source text: ID:nPn6WdvDya
Further company coverage: CIPL.NS
(([email protected];))
March 19 (Reuters) - Cipla Ltd CIPL.NS:
CIPLA - APPROVED INVESTMENT UPTO USD 100 MILLION IN EQUITY SHARE CAPITAL OF CIPLA (EU) LIMITED
CIPLA- APPROVED INVESTMENT UPTO USD 100 MILLION IN THE EQUITY SHARE CAPITAL OF CIPLA (EU) LIMITED
CIPLA - DESIGNATES P R RAMESH AS VICE-CHAIRMAN EFFECTIVE 1 APRIL 2026
CIPLA - APPROVES SCHEME OF AMALGAMATION OF INZPERA HEALTHSCIENCES LIMITED WITH CIPLA
Source text: ID:nNSE8YvWkL
Further company coverage: CIPL.NS
(([email protected];))
March 19 (Reuters) - Cipla Ltd CIPL.NS:
CIPLA - APPROVED INVESTMENT UPTO USD 100 MILLION IN EQUITY SHARE CAPITAL OF CIPLA (EU) LIMITED
CIPLA- APPROVED INVESTMENT UPTO USD 100 MILLION IN THE EQUITY SHARE CAPITAL OF CIPLA (EU) LIMITED
CIPLA - DESIGNATES P R RAMESH AS VICE-CHAIRMAN EFFECTIVE 1 APRIL 2026
CIPLA - APPROVES SCHEME OF AMALGAMATION OF INZPERA HEALTHSCIENCES LIMITED WITH CIPLA
Source text: ID:nNSE8YvWkL
Further company coverage: CIPL.NS
(([email protected];))
March 16 (Reuters) - Fennec Pharmaceuticals Inc FENC.O:
FENNEC PHARMACEUTICALS ANNOUNCES SETTLEMENT AGREEMENT RESOLVING PEDMARK PATENT LITIGATION
FENNEC PHARMACEUTICALS INC - CIPLA BARRED FROM MARKETING GENERIC SODIUM THIOSULFATE UNTIL SEPTEMBER 1, 2033
FENNEC PHARMACEUTICALS INC: UNDER TERMS OF SETTLEMENT, LAWSUIT WILL BE DISMISSED WITH EACH PARTY BEARING THEIR OWN COSTS
Source text: ID:nGNX9TGBKl
Further company coverage: FENC.O
(([email protected];))
March 16 (Reuters) - Fennec Pharmaceuticals Inc FENC.O:
FENNEC PHARMACEUTICALS ANNOUNCES SETTLEMENT AGREEMENT RESOLVING PEDMARK PATENT LITIGATION
FENNEC PHARMACEUTICALS INC - CIPLA BARRED FROM MARKETING GENERIC SODIUM THIOSULFATE UNTIL SEPTEMBER 1, 2033
FENNEC PHARMACEUTICALS INC: UNDER TERMS OF SETTLEMENT, LAWSUIT WILL BE DISMISSED WITH EACH PARTY BEARING THEIR OWN COSTS
Source text: ID:nGNX9TGBKl
Further company coverage: FENC.O
(([email protected];))
Changes dateline, updates with CSL's expansion
March 9 (Reuters) - Global drugmakers are ramping up U.S. manufacturing and stockpiling inventory as the Trump administration considers a 100% tariff on imported branded and patented medicines.
Although enforcement is delayed for companies investing in U.S. manufacturing, the policy has already prompted fast-tracked projects, price cuts and direct-to-consumer sales.
Pfizer and AstraZeneca secured multi-year tariff exemptions through pricing deals and commitments to the new TrumpRx.gov platform. Eli Lilly, Johnson & Johnson and Merck have pledged billions to expand U.S. operations to avoid penalties.
Here's what drugmakers are doing to mitigate supply-chain risks and reassure investors:
Pfizer PFE.N
Pfizer reached a deal with President Donald Trump on September 30 to invest $70 billion in research and development and domestic manufacturing, and received a three-year grace period exempting its products from the pharmaceutical-targeted tariffs.
GSK GSK.L
The London-based drugmaker plans to invest $30 billion in U.S. research and development and supply chain infrastructure over five years.
Eli Lilly LLY.N
U.S. President Donald Trump said in January that Eli Lilly plans to build six plants in the United States.
Lilly said last year that it planned to spend at least $27 billion to build four U.S. plants to expand production and bolster medical supply chains. The company has since announced details on three plants, in Alabama, Virginia and Texas.
Lilly in January said it will build a $3.5 billion pharmaceutical manufacturing facility in Pennsylvania, its fourth new site, in an effort to expand U.S. production and bolster medical supply chains.
Johnson & Johnson JNJ.N
The drugmaker plans to raise U.S. investments by 25%, totaling $55 billion, over the next four years. It plans to build four plants, including one at Wilson, North Carolina, and another at Tokyo-based Fujifilm Biotechnologies' manufacturing site in Holly Springs, North Carolina, over the next 10 years.
The company said in February it would invest more than $1 billion to build a new cell therapy facility in Pennsylvania, part of its larger plans announced last year to scale up U.S. manufacturing.
Roche ROG.S
The Swiss drugmaker said in April last year it would invest $50 billion in the U.S. over the next five years.
A month later, it announced an additional $550 million investment to expand its Indianapolis diagnostics manufacturing hub. The expansion will span Indiana, Pennsylvania, Massachusetts, and California, creating more than 12,000 jobs.
In January, Roche said it will more than double its investment in its drug manufacturing facility in Holly Springs, North Carolina, to about $2 billion, up from the over $700 million announced in May 2025.
AstraZeneca AZN.L
The Anglo-Swedish drugmaker will invest $50 billion on U.S. manufacturing by 2030. The investment will fund a new drug substance facility in Virginia, its largest single-site global investment, alongside expansions in Maryland, Massachusetts, California, Indiana and Texas.
It has already started technology transfers and is managing inventory in 2025 to minimize any tariff hit. Company executives have said the impact would be "very short-lived."
Novartis NOVN.S
The Swiss drugmaker plans to spend $23 billion to build and expand 10 facilities in the U.S. over the next five years. This includes building six new manufacturing plants and expanding its San Diego research and development site, which is expected to create more than 1,000 jobs.
Sanofi SASY.PA
The French drugmaker plans to invest at least $20 billion in the U.S. through 2030 to boost manufacturing and research. Sanofi plans to expand its U.S. manufacturing capacity through direct investments in the company's sites and partnerships with other domestic manufacturers.
Chief Financial Officer François Roger said in July the potential tariffs are expected to have a limited impact in 2025, as the company already has inventory in place in the U.S.
Biogen BIIB.O
The U.S. drugmaker will invest $2 billion more in its existing manufacturing plants in North Carolina, adding capacity for gene-targeting therapies and automation. The company has seven factories in the state, with an eighth set to begin operations in late 2025.
Merck MRK.N
The U.S. drugmaker has begun building a $3 billion pharmaceutical manufacturing plant in Virginia as part of its over $70 billion investment to expand domestic manufacturing and research and development.
It will also invest $1 billion in a new Delaware plant to make biologics and cancer drug Keytruda, to boost U.S. production and potentially create over 4,500 jobs. It also opened a $1 billion facility at its North Carolina site in March.
Merck's animal health unit will invest $895 million to expand its Kansas manufacturing and R&D site, part of a broader $9 billion U.S. investment through 2028.
CEO Robert Davis in July flagged minimal impact from potential tariffs in 2025, and that the company remained well-positioned due to inventory management and moving of manufacturing to the U.S.
Amgen AMGN.O
The U.S.-based biopharma firm plans to invest $900 million to expand its Ohio manufacturing facility, bringing total investment in the state to $1.4 billion and adding 750 jobs. In December, the company committed $1 billion to build a second facility in Holly Springs, North Carolina.
Amgen said in September it is investing more than $600 million to build a new research and development center at its headquarters in Thousand Oaks, California.
The drugmaker announced it will invest $650 million to expand drug manufacturing at its facility in Juncos, Puerto Rico, a move expected to create nearly 750 jobs.
Novo Nordisk NOVOb.CO
The Danish pharmaceutical company said in August its strong U.S. manufacturing footprint positions it well for tariff challenges, describing itself as "very U.S.-centric and U.S.-focused".
AbbVie ABBV.N
U.S. drugmaker AbbVie ABBV.N said in January it has committed $100 billion over the next decade to U.S.-based research and development as part of its three-year deal with the Trump administration to reduce drug prices.
It has 11 manufacturing sites in the U.S. and has said it is "fairly insulated" from any tariff impact this year, given inventory management actions.
The company said in February that it plans to invest $380 million to build two manufacturing facilities at its current North Chicago, Illinois, campus, to support the production of its neuroscience and obesity medications.
Gilead Sciences GILD.O
Earlier this year, the drugmaker announced $11 billion in new planned investment in the U.S. to add to its domestic manufacturing and research heft, taking its total pledged investment to $32 billion.
Gilead said in September that it started work on a pharmaceutical development and manufacturing hub at its headquarters in Foster City, California, in addition to which, it is currently developing two other sites.
Cipla CIPL.NS
The Indian drugmaker is expanding its U.S. manufacturing footprint by investing in capacity expansion for complex respiratory products at its advanced facilities in Fall River, Massachusetts, and Central Islip, New York.
CSL CSL.AX
Australia's CSL said in November it would invest $1.5 billion in the U.S. to manufacture plasma-derived therapies, expanding its footprint in the country over the next five years.
In March, the company announced the expansion of its plasma therapy manufacturing facility in Kankakee, Illinois, which is expected to be operational by 2031.
(Reporting by Siddhi Mahatole, Kamal Choudhury, Puyaan Singh, Sneha S K and Sahil Pandey in Bengaluru; Editing by Tasim Zahid, Sahal Muhammed, Shinjini Ganguli and Maju Samuel)
(([email protected];))
Changes dateline, updates with CSL's expansion
March 9 (Reuters) - Global drugmakers are ramping up U.S. manufacturing and stockpiling inventory as the Trump administration considers a 100% tariff on imported branded and patented medicines.
Although enforcement is delayed for companies investing in U.S. manufacturing, the policy has already prompted fast-tracked projects, price cuts and direct-to-consumer sales.
Pfizer and AstraZeneca secured multi-year tariff exemptions through pricing deals and commitments to the new TrumpRx.gov platform. Eli Lilly, Johnson & Johnson and Merck have pledged billions to expand U.S. operations to avoid penalties.
Here's what drugmakers are doing to mitigate supply-chain risks and reassure investors:
Pfizer PFE.N
Pfizer reached a deal with President Donald Trump on September 30 to invest $70 billion in research and development and domestic manufacturing, and received a three-year grace period exempting its products from the pharmaceutical-targeted tariffs.
GSK GSK.L
The London-based drugmaker plans to invest $30 billion in U.S. research and development and supply chain infrastructure over five years.
Eli Lilly LLY.N
U.S. President Donald Trump said in January that Eli Lilly plans to build six plants in the United States.
Lilly said last year that it planned to spend at least $27 billion to build four U.S. plants to expand production and bolster medical supply chains. The company has since announced details on three plants, in Alabama, Virginia and Texas.
Lilly in January said it will build a $3.5 billion pharmaceutical manufacturing facility in Pennsylvania, its fourth new site, in an effort to expand U.S. production and bolster medical supply chains.
Johnson & Johnson JNJ.N
The drugmaker plans to raise U.S. investments by 25%, totaling $55 billion, over the next four years. It plans to build four plants, including one at Wilson, North Carolina, and another at Tokyo-based Fujifilm Biotechnologies' manufacturing site in Holly Springs, North Carolina, over the next 10 years.
The company said in February it would invest more than $1 billion to build a new cell therapy facility in Pennsylvania, part of its larger plans announced last year to scale up U.S. manufacturing.
Roche ROG.S
The Swiss drugmaker said in April last year it would invest $50 billion in the U.S. over the next five years.
A month later, it announced an additional $550 million investment to expand its Indianapolis diagnostics manufacturing hub. The expansion will span Indiana, Pennsylvania, Massachusetts, and California, creating more than 12,000 jobs.
In January, Roche said it will more than double its investment in its drug manufacturing facility in Holly Springs, North Carolina, to about $2 billion, up from the over $700 million announced in May 2025.
AstraZeneca AZN.L
The Anglo-Swedish drugmaker will invest $50 billion on U.S. manufacturing by 2030. The investment will fund a new drug substance facility in Virginia, its largest single-site global investment, alongside expansions in Maryland, Massachusetts, California, Indiana and Texas.
It has already started technology transfers and is managing inventory in 2025 to minimize any tariff hit. Company executives have said the impact would be "very short-lived."
Novartis NOVN.S
The Swiss drugmaker plans to spend $23 billion to build and expand 10 facilities in the U.S. over the next five years. This includes building six new manufacturing plants and expanding its San Diego research and development site, which is expected to create more than 1,000 jobs.
Sanofi SASY.PA
The French drugmaker plans to invest at least $20 billion in the U.S. through 2030 to boost manufacturing and research. Sanofi plans to expand its U.S. manufacturing capacity through direct investments in the company's sites and partnerships with other domestic manufacturers.
Chief Financial Officer François Roger said in July the potential tariffs are expected to have a limited impact in 2025, as the company already has inventory in place in the U.S.
Biogen BIIB.O
The U.S. drugmaker will invest $2 billion more in its existing manufacturing plants in North Carolina, adding capacity for gene-targeting therapies and automation. The company has seven factories in the state, with an eighth set to begin operations in late 2025.
Merck MRK.N
The U.S. drugmaker has begun building a $3 billion pharmaceutical manufacturing plant in Virginia as part of its over $70 billion investment to expand domestic manufacturing and research and development.
It will also invest $1 billion in a new Delaware plant to make biologics and cancer drug Keytruda, to boost U.S. production and potentially create over 4,500 jobs. It also opened a $1 billion facility at its North Carolina site in March.
Merck's animal health unit will invest $895 million to expand its Kansas manufacturing and R&D site, part of a broader $9 billion U.S. investment through 2028.
CEO Robert Davis in July flagged minimal impact from potential tariffs in 2025, and that the company remained well-positioned due to inventory management and moving of manufacturing to the U.S.
Amgen AMGN.O
The U.S.-based biopharma firm plans to invest $900 million to expand its Ohio manufacturing facility, bringing total investment in the state to $1.4 billion and adding 750 jobs. In December, the company committed $1 billion to build a second facility in Holly Springs, North Carolina.
Amgen said in September it is investing more than $600 million to build a new research and development center at its headquarters in Thousand Oaks, California.
The drugmaker announced it will invest $650 million to expand drug manufacturing at its facility in Juncos, Puerto Rico, a move expected to create nearly 750 jobs.
Novo Nordisk NOVOb.CO
The Danish pharmaceutical company said in August its strong U.S. manufacturing footprint positions it well for tariff challenges, describing itself as "very U.S.-centric and U.S.-focused".
AbbVie ABBV.N
U.S. drugmaker AbbVie ABBV.N said in January it has committed $100 billion over the next decade to U.S.-based research and development as part of its three-year deal with the Trump administration to reduce drug prices.
It has 11 manufacturing sites in the U.S. and has said it is "fairly insulated" from any tariff impact this year, given inventory management actions.
The company said in February that it plans to invest $380 million to build two manufacturing facilities at its current North Chicago, Illinois, campus, to support the production of its neuroscience and obesity medications.
Gilead Sciences GILD.O
Earlier this year, the drugmaker announced $11 billion in new planned investment in the U.S. to add to its domestic manufacturing and research heft, taking its total pledged investment to $32 billion.
Gilead said in September that it started work on a pharmaceutical development and manufacturing hub at its headquarters in Foster City, California, in addition to which, it is currently developing two other sites.
Cipla CIPL.NS
The Indian drugmaker is expanding its U.S. manufacturing footprint by investing in capacity expansion for complex respiratory products at its advanced facilities in Fall River, Massachusetts, and Central Islip, New York.
CSL CSL.AX
Australia's CSL said in November it would invest $1.5 billion in the U.S. to manufacture plasma-derived therapies, expanding its footprint in the country over the next five years.
In March, the company announced the expansion of its plasma therapy manufacturing facility in Kankakee, Illinois, which is expected to be operational by 2031.
(Reporting by Siddhi Mahatole, Kamal Choudhury, Puyaan Singh, Sneha S K and Sahil Pandey in Bengaluru; Editing by Tasim Zahid, Sahal Muhammed, Shinjini Ganguli and Maju Samuel)
(([email protected];))
South Africa aims to boost access to HIV prevention drug nationally and regionally
Lenacapavir could help bring an end to 44-year old epidemic, experts say
Sub-Saharan Africa remains epicentre of HIV pandemic
By Jennifer Rigby
LONDON, March 5 (Reuters) - South Africa is asking local drugmakers to start a process to make Gilead Sciences’ long-acting HIV prevention drug, lenacapavir, domestically, in a push to bring production to the region where it is most needed.
The government is working alongside international partners, including Unitaid and the United States Pharmacopoeia, to identify which local company could make the twice-yearly injection safely, effectively and affordably, and provide any support needed. They will then recommend that company to Gilead.
Gilead, a U.S. pharmaceutical company, granted six voluntary licences in 2024 to generic manufacturers across India, Egypt and Pakistan to produce and supply the drug to 120 low- and middle-income countries. These included South Africa, although there was criticism that no South African drugmakers were included.
A licence for a South African company would be the seventh such deal, potentially boosting access to a drug many HIV/AIDS experts have said could help bring an end to the 44-year-old pandemic by slashing the numbers of new infections.
Gilead said it has been open to adding an additional voluntary license for local manufacturing in Sub-Saharan Africa. "Gilead will review the proposals and assess whether required quality standards can be met before any voluntary license is granted," the company said in an email.
AFRICA REMAINS EPICENTRE OF HIV PANDEMIC
Despite progress, the African region remains the epicentre of the HIV pandemic. South Africa has the highest number of people affected at 8 million – around one in five adults – living with the virus. Several companies in South Africa already make HIV treatments or sterile injectables, like Aspen Pharmacare.
Paul Mashatile, chair of the South African National AIDS Council and deputy president, said making the drug in South Africa would benefit the whole region.
“Africa can no longer rely on medicines produced elsewhere for diseases that affect us most,” said Kenyan President William Ruto, African Union lead on local manufacturing of health commodities.
ACCESS CHALLENGES
In the past, low- and middle-income countries waited years for HIV drugs available in richer nations. Lenacapavir is already available in some African countries through an initiative supported by The Global Fund to Fight AIDS, Tuberculosis and Malaria and the U.S. government, but demand is expected to outstrip supply until the generic manufacturers start making the drug.
Those agreements also faced some criticism for excluding middle-income countries like Brazil. A South African company could try to expand access there, too, Unitaid said.
“It’s an opportunity to open the door further,” said Unitaid’s director of program, Robert Matiru, although he said a licence for a South African company was the key aim.
(Reporting by Jennifer Rigby, additional reporting by Nellie Peyton and Nqobile Dludla in Johannesburg and Deena Beasley in Los Angeles; Editing by Kirsten Donovan)
South Africa aims to boost access to HIV prevention drug nationally and regionally
Lenacapavir could help bring an end to 44-year old epidemic, experts say
Sub-Saharan Africa remains epicentre of HIV pandemic
By Jennifer Rigby
LONDON, March 5 (Reuters) - South Africa is asking local drugmakers to start a process to make Gilead Sciences’ long-acting HIV prevention drug, lenacapavir, domestically, in a push to bring production to the region where it is most needed.
The government is working alongside international partners, including Unitaid and the United States Pharmacopoeia, to identify which local company could make the twice-yearly injection safely, effectively and affordably, and provide any support needed. They will then recommend that company to Gilead.
Gilead, a U.S. pharmaceutical company, granted six voluntary licences in 2024 to generic manufacturers across India, Egypt and Pakistan to produce and supply the drug to 120 low- and middle-income countries. These included South Africa, although there was criticism that no South African drugmakers were included.
A licence for a South African company would be the seventh such deal, potentially boosting access to a drug many HIV/AIDS experts have said could help bring an end to the 44-year-old pandemic by slashing the numbers of new infections.
Gilead said it has been open to adding an additional voluntary license for local manufacturing in Sub-Saharan Africa. "Gilead will review the proposals and assess whether required quality standards can be met before any voluntary license is granted," the company said in an email.
AFRICA REMAINS EPICENTRE OF HIV PANDEMIC
Despite progress, the African region remains the epicentre of the HIV pandemic. South Africa has the highest number of people affected at 8 million – around one in five adults – living with the virus. Several companies in South Africa already make HIV treatments or sterile injectables, like Aspen Pharmacare.
Paul Mashatile, chair of the South African National AIDS Council and deputy president, said making the drug in South Africa would benefit the whole region.
“Africa can no longer rely on medicines produced elsewhere for diseases that affect us most,” said Kenyan President William Ruto, African Union lead on local manufacturing of health commodities.
ACCESS CHALLENGES
In the past, low- and middle-income countries waited years for HIV drugs available in richer nations. Lenacapavir is already available in some African countries through an initiative supported by The Global Fund to Fight AIDS, Tuberculosis and Malaria and the U.S. government, but demand is expected to outstrip supply until the generic manufacturers start making the drug.
Those agreements also faced some criticism for excluding middle-income countries like Brazil. A South African company could try to expand access there, too, Unitaid said.
“It’s an opportunity to open the door further,” said Unitaid’s director of program, Robert Matiru, although he said a licence for a South African company was the key aim.
(Reporting by Jennifer Rigby, additional reporting by Nellie Peyton and Nqobile Dludla in Johannesburg and Deena Beasley in Los Angeles; Editing by Kirsten Donovan)
March 2 (Reuters) - Cipla Ltd CIPL.NS:
INCORPORATED SUBSIDIARY CIPLA MIDDLE EAST COMPANY IN KINGDOM OF SAUDI ARABIA
Source text: ID:nnAZN4SJ5GY
Further company coverage: CIPL.NS
(([email protected];;))
March 2 (Reuters) - Cipla Ltd CIPL.NS:
INCORPORATED SUBSIDIARY CIPLA MIDDLE EAST COMPANY IN KINGDOM OF SAUDI ARABIA
Source text: ID:nnAZN4SJ5GY
Further company coverage: CIPL.NS
(([email protected];;))
Feb 27 (Reuters) - Cipla Ltd CIPL.NS:
CIPLA STRENGTHENS US PORTFOLIO WITH THE LAUNCH OF GENERIC SAXENDA® (LIRAGLUTIDE INJECTION) FOR WEIGHT MANAGEMENT THERAPY
CIPLA: TO LAUNCH GENERIC SAXENDA ON AN IMMEDIATE BASIS
Source text: ID:nPn2VJ63Sa
Further company coverage: CIPL.NS
(([email protected];))
Feb 27 (Reuters) - Cipla Ltd CIPL.NS:
CIPLA STRENGTHENS US PORTFOLIO WITH THE LAUNCH OF GENERIC SAXENDA® (LIRAGLUTIDE INJECTION) FOR WEIGHT MANAGEMENT THERAPY
CIPLA: TO LAUNCH GENERIC SAXENDA ON AN IMMEDIATE BASIS
Source text: ID:nPn2VJ63Sa
Further company coverage: CIPL.NS
(([email protected];))
Pulmatrix reported FY 2025 results with no revenue, as wind-down activities tied to its Cipla agreement for the PUR1900 program were completed in FY 2024. Net loss was USD 5.2 million in FY 2025, with R&D expense of USD 38,000 and G&A expense of USD 5.1 million. Cash and cash equivalents were USD 4.1 million as of Dec. 31, 2025, and Pulmatrix said its cash position is sufficient to fund operations into Q1 2027. On the corporate front, Pulmatrix said it is continuing efforts to license or monetize its iSPERSE technology and clinical assets, including PUR3100 (a Phase 2-ready inhaled dihydroergotamine acute migraine program with an FDA-cleared IND and “study may proceed” letter), PUR1800 (a narrow spectrum kinase inhibitor for AECOPD with Phase 1b results indicating it was well-tolerated), and PUR1900 (inhaled itraconazole), for which partner Cipla completed a Phase 2 study in India and received approval to proceed to Phase 3; Pulmatrix is eligible for 2% royalties on potential future net sales by Cipla outside the U.S. Pulmatrix also provided an update on its proposed merger with Cullgen, noting stockholder approval was received in June 2025, and that the parties waived the merger agreement’s “no solicitation” clause in December 2025 while continuing to seek China Securities Regulatory Commission approval and other customary closing conditions.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulmatrix Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602260805PR_NEWS_USPR_____NE96459) on February 26, 2026, and is solely responsible for the information contained therein.
Pulmatrix reported FY 2025 results with no revenue, as wind-down activities tied to its Cipla agreement for the PUR1900 program were completed in FY 2024. Net loss was USD 5.2 million in FY 2025, with R&D expense of USD 38,000 and G&A expense of USD 5.1 million. Cash and cash equivalents were USD 4.1 million as of Dec. 31, 2025, and Pulmatrix said its cash position is sufficient to fund operations into Q1 2027. On the corporate front, Pulmatrix said it is continuing efforts to license or monetize its iSPERSE technology and clinical assets, including PUR3100 (a Phase 2-ready inhaled dihydroergotamine acute migraine program with an FDA-cleared IND and “study may proceed” letter), PUR1800 (a narrow spectrum kinase inhibitor for AECOPD with Phase 1b results indicating it was well-tolerated), and PUR1900 (inhaled itraconazole), for which partner Cipla completed a Phase 2 study in India and received approval to proceed to Phase 3; Pulmatrix is eligible for 2% royalties on potential future net sales by Cipla outside the U.S. Pulmatrix also provided an update on its proposed merger with Cullgen, noting stockholder approval was received in June 2025, and that the parties waived the merger agreement’s “no solicitation” clause in December 2025 while continuing to seek China Securities Regulatory Commission approval and other customary closing conditions.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulmatrix Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602260805PR_NEWS_USPR_____NE96459) on February 26, 2026, and is solely responsible for the information contained therein.
** India's Cipla CIPL.NS drops ~2% to 1,320 rupees, top loser on pharma index .NIPHARM, which is up 0.4%
** U.S. FDA concluded inspection at a facility of Pharmathen, Cipla's exclusive contract manufacturer for its key tumour therapy Lanreotide, indicating it as "official action indicated"
** Classification means regulatory or administrative actions are recommended - regulator's website
** Greece-based Pharmathen had temporarily paused production in Q3 to work through FDA remediation requirements, resulting in CIPL missing results estimates
** Avg rating on CIPL at "hold"; median PT is 1,445 rupees - data compiled by LSEG
** YTD, stock down 12.2% vs pharma index's 0.8% drop
(Reporting by Kashish Tandon in Bengaluru)
** India's Cipla CIPL.NS drops ~2% to 1,320 rupees, top loser on pharma index .NIPHARM, which is up 0.4%
** U.S. FDA concluded inspection at a facility of Pharmathen, Cipla's exclusive contract manufacturer for its key tumour therapy Lanreotide, indicating it as "official action indicated"
** Classification means regulatory or administrative actions are recommended - regulator's website
** Greece-based Pharmathen had temporarily paused production in Q3 to work through FDA remediation requirements, resulting in CIPL missing results estimates
** Avg rating on CIPL at "hold"; median PT is 1,445 rupees - data compiled by LSEG
** YTD, stock down 12.2% vs pharma index's 0.8% drop
(Reporting by Kashish Tandon in Bengaluru)
Feb 20 (Reuters) - Cipla Ltd CIPL.NS:
LIC RAISES STAKE IN CIPLA TO 9.091% FROM 7.055% BETWEEN NOV AND FEB- FILING
Source text: ID:nBSE3SBW2S
Further company coverage: CIPL.NS
(([email protected];))
Feb 20 (Reuters) - Cipla Ltd CIPL.NS:
LIC RAISES STAKE IN CIPLA TO 9.091% FROM 7.055% BETWEEN NOV AND FEB- FILING
Source text: ID:nBSE3SBW2S
Further company coverage: CIPL.NS
(([email protected];))
Eli Lilly wants to export drugs made in India to markets across the world
It has already committed to invest $1 billion in contract manufacturing in the country
Also plans to bring other products to India, such as Alzheimer's drug donanemab
Adds executive's complete designation in paragraph 4
By Rishika Sadam and Kashish Tandon
HYDERABAD, Feb 17 (Reuters) - Mounjaro-maker Eli Lilly LLY.N wants to turn India into a hub for its global supply chain, a senior executive at the U.S. drugmaker said, as part of its previously committed $1 billion investment to contract manufacturing in the country.
Sales of the blockbuster weight-loss drug doubled within months of its launch in the South Asian country and became its top-selling medicine by value, underscoring the growing popularity of obesity treatments in a country projected to have the world's second-largest obese population by 2050.
The company, which does not currently operate its own manufacturing facility in India, plans to export locally produced drugs to markets across the world as part of its broader supply network, drawing on the country's robust contract manufacturing setup.
"We are actually looking at India to be a hub, part of our global supply chain, and therefore supplying the world," Winselow Tucker, president and general manager, Eli Lilly and Company (India), told Reuters on the sidelines of the BioAsia conference in Hyderabad.
"We will continue to look at that (investment) and scale that over time," Tucker said, declining to name contract manufacturers or discuss plans for a dedicated plant.
The company also plans to bring additional products to India, including its Alzheimer's drug donanemab and potential future obesity treatments such as its experimental oral weight-loss drug orforglipron, pending regulatory approvals, Tucker said.
PRICE RACE
In India, Lilly competes with Danish drugmaker Novo Nordisk NOVOb.CO, which makes Wegovy.
The world's most populous nation is set for a weight-loss drug boom this year as local firms race to launch cheaper, generic versions of Wegovy after Novo's patent on semaglutide expires in India next month.
Novo cut Wegovy's price by up to 37% last year to defend market share.
Tucker dismissed concerns about Mounjaro facing similar pressure, saying the drug's composition offered superior efficacy and would keep it competitive.
"We have priced it (Mounjaro) for value, and we believe it is priced appropriately," Tucker said.
Lilly is instead focused on boosting digital and social media campaigns to raise obesity awareness and expand Mounjaro's reach in smaller Indian cities. It has widened its distribution beyond major metros through partnerships, such as with Indian drugmaker Cipla CIPL.NS and with digital health platforms Tata 1MG, Practo and Apollo.
(Reporting by Kashish Tandon and Rishika Sadam in Hyderabad; Editing by Dhanya Skariachan and Janane Venkatraman)
(([email protected]; 8800437922;))
Eli Lilly wants to export drugs made in India to markets across the world
It has already committed to invest $1 billion in contract manufacturing in the country
Also plans to bring other products to India, such as Alzheimer's drug donanemab
Adds executive's complete designation in paragraph 4
By Rishika Sadam and Kashish Tandon
HYDERABAD, Feb 17 (Reuters) - Mounjaro-maker Eli Lilly LLY.N wants to turn India into a hub for its global supply chain, a senior executive at the U.S. drugmaker said, as part of its previously committed $1 billion investment to contract manufacturing in the country.
Sales of the blockbuster weight-loss drug doubled within months of its launch in the South Asian country and became its top-selling medicine by value, underscoring the growing popularity of obesity treatments in a country projected to have the world's second-largest obese population by 2050.
The company, which does not currently operate its own manufacturing facility in India, plans to export locally produced drugs to markets across the world as part of its broader supply network, drawing on the country's robust contract manufacturing setup.
"We are actually looking at India to be a hub, part of our global supply chain, and therefore supplying the world," Winselow Tucker, president and general manager, Eli Lilly and Company (India), told Reuters on the sidelines of the BioAsia conference in Hyderabad.
"We will continue to look at that (investment) and scale that over time," Tucker said, declining to name contract manufacturers or discuss plans for a dedicated plant.
The company also plans to bring additional products to India, including its Alzheimer's drug donanemab and potential future obesity treatments such as its experimental oral weight-loss drug orforglipron, pending regulatory approvals, Tucker said.
PRICE RACE
In India, Lilly competes with Danish drugmaker Novo Nordisk NOVOb.CO, which makes Wegovy.
The world's most populous nation is set for a weight-loss drug boom this year as local firms race to launch cheaper, generic versions of Wegovy after Novo's patent on semaglutide expires in India next month.
Novo cut Wegovy's price by up to 37% last year to defend market share.
Tucker dismissed concerns about Mounjaro facing similar pressure, saying the drug's composition offered superior efficacy and would keep it competitive.
"We have priced it (Mounjaro) for value, and we believe it is priced appropriately," Tucker said.
Lilly is instead focused on boosting digital and social media campaigns to raise obesity awareness and expand Mounjaro's reach in smaller Indian cities. It has widened its distribution beyond major metros through partnerships, such as with Indian drugmaker Cipla CIPL.NS and with digital health platforms Tata 1MG, Practo and Apollo.
(Reporting by Kashish Tandon and Rishika Sadam in Hyderabad; Editing by Dhanya Skariachan and Janane Venkatraman)
(([email protected]; 8800437922;))
Repeats story from 13th Feburary with no changes to text
By Rishika Sadam
Feb 16 (Reuters) - Biocon BION.NS is aiming for high-double-digit percentage revenue growth as the Indian pharmaceutical firm prepares to launch generic versions of weight-loss drugs globally even as it remains cautious about an early rollout in the home market, a top company executive told Reuters.
The company is counting on demand for obesity medicines as it expands a pipeline that includes copycat versions of Novo Nordisk's NOVOb.CO Wegovy, whose patent for semaglutide in a few markets expires in 2026.
Indian drugmakers, including Dr Reddy's REDY.NS, Lupin LUPN.NS, Sun Pharmaceutical SUN.NS and at least half a dozen others are racing to bring cheaper copies to markets once the active compound goes off patent.
Bengaluru-based Biocon is targeting a U.S. launch of generic liraglutide in the first quarter of the next financial year, CEO Siddharth Mittal said in an interview on Friday. Liraglutide is also used for obesity treatment.
It aims to launch generic Wegovy in Canada next year, subject to regulatory approval, Mittal said. It is also planning launches over the next few years in India, Brazil, Mexico, Turkey, and parts of the Middle East and Latin America.
The company, however, is cautious about an early start in India due to fierce price competition and local clinical trial requirements, Mittal said.
"There's going to be fierce competition in India," Mittal said, citing low price expectations. He said Biocon is exploring approval in a specific overseas market first, which could help it seek a clinical trial waiver in India under local rules.
In India, Biocon would need to run a late-stage clinical trial before launch. The company is weighing whether that cost would be justified, Mittal said, or whether it should seek a waiver.
The obesity medicines market, according to several forecasts, is expected to reach at least $150 billion globally by the early 2030s, and analysts expect generic versions to be priced at least 60% below the originator products.
Biocon expects high double-digit percentage revenue growth, Mittal said. The company's annual revenue grew 5.4% in fiscal 2025 from a year ago, but it has been growing in early double-digits on a quarter-on-quarter basis.
India is not Biocon's main market. The company derives significant share of revenue from the United States and parts of Europe.
(Reporting by Rishika Sadam; Editing by Tasim Zahid)
(([email protected];))
Repeats story from 13th Feburary with no changes to text
By Rishika Sadam
Feb 16 (Reuters) - Biocon BION.NS is aiming for high-double-digit percentage revenue growth as the Indian pharmaceutical firm prepares to launch generic versions of weight-loss drugs globally even as it remains cautious about an early rollout in the home market, a top company executive told Reuters.
The company is counting on demand for obesity medicines as it expands a pipeline that includes copycat versions of Novo Nordisk's NOVOb.CO Wegovy, whose patent for semaglutide in a few markets expires in 2026.
Indian drugmakers, including Dr Reddy's REDY.NS, Lupin LUPN.NS, Sun Pharmaceutical SUN.NS and at least half a dozen others are racing to bring cheaper copies to markets once the active compound goes off patent.
Bengaluru-based Biocon is targeting a U.S. launch of generic liraglutide in the first quarter of the next financial year, CEO Siddharth Mittal said in an interview on Friday. Liraglutide is also used for obesity treatment.
It aims to launch generic Wegovy in Canada next year, subject to regulatory approval, Mittal said. It is also planning launches over the next few years in India, Brazil, Mexico, Turkey, and parts of the Middle East and Latin America.
The company, however, is cautious about an early start in India due to fierce price competition and local clinical trial requirements, Mittal said.
"There's going to be fierce competition in India," Mittal said, citing low price expectations. He said Biocon is exploring approval in a specific overseas market first, which could help it seek a clinical trial waiver in India under local rules.
In India, Biocon would need to run a late-stage clinical trial before launch. The company is weighing whether that cost would be justified, Mittal said, or whether it should seek a waiver.
The obesity medicines market, according to several forecasts, is expected to reach at least $150 billion globally by the early 2030s, and analysts expect generic versions to be priced at least 60% below the originator products.
Biocon expects high double-digit percentage revenue growth, Mittal said. The company's annual revenue grew 5.4% in fiscal 2025 from a year ago, but it has been growing in early double-digits on a quarter-on-quarter basis.
India is not Biocon's main market. The company derives significant share of revenue from the United States and parts of Europe.
(Reporting by Rishika Sadam; Editing by Tasim Zahid)
(([email protected];))
By Rishika Sadam
Feb 13 (Reuters) - Biocon BION.NS is aiming for high-double-digit percentage revenue growth as the Indian pharmaceutical firm prepares to launch generic versions of weight-loss drugs globally even as it remains cautious about an early rollout in the home market, a top company executive told Reuters.
The company is counting on demand for obesity medicines as it expands a pipeline that includes copycat versions of Novo Nordisk's NOVOb.CO Wegovy, whose patent for semaglutide in a few markets expires in 2026.
Indian drugmakers, including Dr Reddy's REDY.NS, Lupin LUPN.NS, Sun Pharmaceutical SUN.NS and at least half a dozen others are racing to bring cheaper copies to markets once the active compound goes off patent.
Bengaluru-based Biocon is targeting a U.S. launch of generic liraglutide in the first quarter of the next financial year, CEO Siddharth Mittal said in an interview on Friday. Liraglutide is also used for obesity treatment.
It aims to launch generic Wegovy in Canada next year, subject to regulatory approval, Mittal said. It is also planning launches over the next few years in India, Brazil, Mexico, Turkey, and parts of the Middle East and Latin America.
The company, however, is cautious about an early start in India due to fierce price competition and local clinical trial requirements, Mittal said.
"There's going to be fierce competition in India," Mittal said, citing low price expectations. He said Biocon is exploring approval in a specific overseas market first, which could help it seek a clinical trial waiver in India under local rules.
In India, Biocon would need to run a late-stage clinical trial before launch. The company is weighing whether that cost would be justified, Mittal said, or whether it should seek a waiver.
The obesity medicines market, according to several forecasts, is expected to reach at least $150 billion globally by the early 2030s, and analysts expect generic versions to be priced at least 60% below the originator products.
Biocon expects high double-digit percentage revenue growth, Mittal said. The company's annual revenue grew 5.4% in fiscal 2025 from a year ago, but it has been growing in early double-digits on a quarter-on-quarter basis.
India is not Biocon's main market. The company derives significant share of revenue from the United States and parts of Europe.
(Reporting by Rishika Sadam; Editing by Tasim Zahid)
(([email protected];))
By Rishika Sadam
Feb 13 (Reuters) - Biocon BION.NS is aiming for high-double-digit percentage revenue growth as the Indian pharmaceutical firm prepares to launch generic versions of weight-loss drugs globally even as it remains cautious about an early rollout in the home market, a top company executive told Reuters.
The company is counting on demand for obesity medicines as it expands a pipeline that includes copycat versions of Novo Nordisk's NOVOb.CO Wegovy, whose patent for semaglutide in a few markets expires in 2026.
Indian drugmakers, including Dr Reddy's REDY.NS, Lupin LUPN.NS, Sun Pharmaceutical SUN.NS and at least half a dozen others are racing to bring cheaper copies to markets once the active compound goes off patent.
Bengaluru-based Biocon is targeting a U.S. launch of generic liraglutide in the first quarter of the next financial year, CEO Siddharth Mittal said in an interview on Friday. Liraglutide is also used for obesity treatment.
It aims to launch generic Wegovy in Canada next year, subject to regulatory approval, Mittal said. It is also planning launches over the next few years in India, Brazil, Mexico, Turkey, and parts of the Middle East and Latin America.
The company, however, is cautious about an early start in India due to fierce price competition and local clinical trial requirements, Mittal said.
"There's going to be fierce competition in India," Mittal said, citing low price expectations. He said Biocon is exploring approval in a specific overseas market first, which could help it seek a clinical trial waiver in India under local rules.
In India, Biocon would need to run a late-stage clinical trial before launch. The company is weighing whether that cost would be justified, Mittal said, or whether it should seek a waiver.
The obesity medicines market, according to several forecasts, is expected to reach at least $150 billion globally by the early 2030s, and analysts expect generic versions to be priced at least 60% below the originator products.
Biocon expects high double-digit percentage revenue growth, Mittal said. The company's annual revenue grew 5.4% in fiscal 2025 from a year ago, but it has been growing in early double-digits on a quarter-on-quarter basis.
India is not Biocon's main market. The company derives significant share of revenue from the United States and parts of Europe.
(Reporting by Rishika Sadam; Editing by Tasim Zahid)
(([email protected];))
Feb 10 (Reuters) - Cipla Ltd CIPL.NS:
CIPLA - USFDA INSPECTION AT INVAGEN MANUFACTURING FACILITY IN HAUPPAUGE, LONG ISLAND, NEW YORK, USA
CIPLA - ON CONCLUSION OF INSPECTION, INVAGEN HAS RECEIVED 2 INSPECTIONAL OBSERVATIONS
Source text: ID:nNSEb8YkN0
Further company coverage: CIPL.NS
(([email protected];))
Feb 10 (Reuters) - Cipla Ltd CIPL.NS:
CIPLA - USFDA INSPECTION AT INVAGEN MANUFACTURING FACILITY IN HAUPPAUGE, LONG ISLAND, NEW YORK, USA
CIPLA - ON CONCLUSION OF INSPECTION, INVAGEN HAS RECEIVED 2 INSPECTIONAL OBSERVATIONS
Source text: ID:nNSEb8YkN0
Further company coverage: CIPL.NS
(([email protected];))
Feb 5 (Reuters) - Cipla Ltd CIPL.NS:
CIPLA - TAX DEPARTMENT INITIATES INSPECTION AT CIPLA FACILITIES
CIPLA - INSPECTION HAS NO FINANCIAL IMPACT ON CIPLA
Source text: ID:nNSE88rNT2
Further company coverage: CIPL.NS
(([email protected];))
Feb 5 (Reuters) - Cipla Ltd CIPL.NS:
CIPLA - TAX DEPARTMENT INITIATES INSPECTION AT CIPLA FACILITIES
CIPLA - INSPECTION HAS NO FINANCIAL IMPACT ON CIPLA
Source text: ID:nNSE88rNT2
Further company coverage: CIPL.NS
(([email protected];))
Changes dateline, adds Eli Lilly details in paragraph 11
Jan 30 (Reuters) - Global drugmakers are ramping up U.S. manufacturing and stockpiling inventory as the Trump administration considers a 100% tariff on imported branded and patented medicines.
Although enforcement is delayed for companies investing in U.S. manufacturing, the policy has already prompted fast-tracked projects, price cuts and direct-to-consumer sales.
Pfizer and AstraZeneca secured multi-year tariff exemptions through pricing deals and commitments to the new TrumpRx.gov platform. Eli Lilly, Johnson & Johnson and Merck have pledged billions to expand U.S. operations to avoid penalties.
Here's what drugmakers are doing to mitigate supply-chain risks and reassure investors:
Pfizer PFE.N
Pfizer reached a deal with President Donald Trump on September 30 to invest $70 billion in research and development and domestic manufacturing, and received a three-year grace period exempting its products from the pharmaceutical-targeted tariffs.
GSK GSK.L
The London-based drugmaker plans to invest $30 billion in U.S. research and development and supply chain infrastructure over five years.
Eli Lilly LLY.N
U.S. President Donald Trump said in January that Eli Lilly plans to build six plants in the United States.
Lilly said last year that it planned to spend at least $27 billion to build four U.S. plants to expand production and bolster medical supply chains. The company has since announced details on three plants, in Alabama, Virginia and Texas.
Johnson & Johnson JNJ.N
The drugmaker plans to raise U.S. investments by 25%, totaling $55 billion, over the next four years. It plans to build four plants, including one at Wilson, North Carolina, and another at Tokyo-based Fujifilm Biotechnologies' manufacturing site in Holly Springs, North Carolina, over the next 10 years.
Locations for the other plants remain undisclosed.
Roche ROG.S
The Swiss drugmaker said in April last year it will invest $50 billion in the U.S. over the next five years.
A month later, it announced an additional $550 million investment to expand its Indianapolis diagnostics manufacturing hub. The expansion will span Indiana, Pennsylvania, Massachusetts, and California, creating more than 12,000 jobs.
In January, Roche said it will more than double its investment in its drug manufacturing facility in Holly Springs, North Carolina, to about $2 billion, up from the over $700 million announced in May 2025.
AstraZeneca AZN.L
The Anglo-Swedish drugmaker will invest $50 billion on U.S. manufacturing by 2030. The investment will fund a new drug substance facility in Virginia, its largest single-site global investment, alongside expansions in Maryland, Massachusetts, California, Indiana and Texas.
It has already started technology transfers and is managing inventory in 2025 to minimize any tariff hit. Company executives have said the impact would be "very short-lived."
Novartis NOVN.S
The Swiss drugmaker plans to spend $23 billion to build and expand 10 facilities in the U.S. over the next five years. This includes building six new manufacturing plants and expanding its San Diego research and development site, which is expected to create more than 1,000 jobs.
Sanofi SASY.PA
The French drugmaker plans to invest at least $20 billion in the U.S. through 2030 to boost manufacturing and research. Sanofi plans to expand its U.S. manufacturing capacity through direct investments in the company's sites and partnerships with other domestic manufacturers.
Chief Financial Officer François Roger said in July the potential tariffs are expected to have a limited impact in 2025, as the company already has inventory in place in the U.S.
Biogen BIIB.O
The U.S. drugmaker will invest $2 billion more in its existing manufacturing plants in North Carolina, adding capacity for gene-targeting therapies and automation. The company has seven factories in the state, with an eighth set to begin operations in late 2025.
Merck MRK.N
The U.S. drugmaker has begun building a $3 billion pharmaceutical manufacturing plant in Virginia as part of its over $70 billion investment to expand domestic manufacturing and research and development in the United States.
It will also invest $1 billion in a new Delaware plant to make biologics and cancer drug Keytruda, to boost U.S. production and potentially create over 4,500 jobs. It also opened a $1 billion facility at its North Carolina site in March.
Merck's animal health unit will invest $895 million to expand its Kansas manufacturing and R&D site, part of a broader $9 billion U.S. investment through 2028.
CEO Robert Davis in July flagged minimal impact from potential tariffs in 2025, and that the company remained well-positioned due to inventory management and moving of manufacturing to the U.S.
Amgen AMGN.O
The U.S.-based biopharma firm plans to invest $900 million to expand its Ohio manufacturing facility, bringing total investment in the state to $1.4 billion and adding 750 jobs. In December, the company committed $1 billion to build a second facility in Holly Springs, North Carolina.
Amgen said in September it is investing more than $600 million to build a new research and development center at its headquarters in Thousand Oaks, California.
The drugmaker announced it will invest $650 million to expand drug manufacturing at its facility in Juncos, Puerto Rico, a move expected to create nearly 750 jobs.
Novo Nordisk NOVOb.CO
The Danish pharmaceutical company said in August its strong U.S. manufacturing footprint positions it well for tariff challenges, describing itself as "very U.S.-centric and U.S.-focused".
AbbVie ABBV.N
U.S. drugmaker AbbVie ABBV.N said in January it has committed $100 billion over the next decade to U.S.-based research and development as part of its three-year deal with the Trump administration to reduce drug prices.
It has 11 manufacturing sites in the U.S. and has said it is "fairly insulated" from any tariff impact this year given inventory management actions.
Gilead Sciences GILD.O
Earlier this year, the drugmaker announced $11 billion in new planned investment in the U.S. to add to its domestic manufacturing and research heft, taking its total pledged investment to $32 billion.
Gilead said in September that it started work on a pharmaceutical development and manufacturing hub at its headquarters in Foster City, California, in addition to which, it is currently developing two other sites.
Cipla CIPL.NS
The Indian drugmaker is expanding its U.S. manufacturing footprint by investing in capacity expansion for complex respiratory products at its advanced facilities in Fall River, Massachusetts, and Central Islip, New York.
CSL CSL.AX
Australia's CSL said in November it would invest $1.5 billion in the U.S. to manufacture plasma-derived therapies, expanding its footprint in the country over the next five years.
(Reporting by Siddhi Mahatole, Kamal Choudhury, Puyaan Singh, Sneha S K and Sahil Pandey in Bengaluru; Editing by Tasim Zahid, Sahal Muhammed and Maju Samuel)
(([email protected];))
Changes dateline, adds Eli Lilly details in paragraph 11
Jan 30 (Reuters) - Global drugmakers are ramping up U.S. manufacturing and stockpiling inventory as the Trump administration considers a 100% tariff on imported branded and patented medicines.
Although enforcement is delayed for companies investing in U.S. manufacturing, the policy has already prompted fast-tracked projects, price cuts and direct-to-consumer sales.
Pfizer and AstraZeneca secured multi-year tariff exemptions through pricing deals and commitments to the new TrumpRx.gov platform. Eli Lilly, Johnson & Johnson and Merck have pledged billions to expand U.S. operations to avoid penalties.
Here's what drugmakers are doing to mitigate supply-chain risks and reassure investors:
Pfizer PFE.N
Pfizer reached a deal with President Donald Trump on September 30 to invest $70 billion in research and development and domestic manufacturing, and received a three-year grace period exempting its products from the pharmaceutical-targeted tariffs.
GSK GSK.L
The London-based drugmaker plans to invest $30 billion in U.S. research and development and supply chain infrastructure over five years.
Eli Lilly LLY.N
U.S. President Donald Trump said in January that Eli Lilly plans to build six plants in the United States.
Lilly said last year that it planned to spend at least $27 billion to build four U.S. plants to expand production and bolster medical supply chains. The company has since announced details on three plants, in Alabama, Virginia and Texas.
Johnson & Johnson JNJ.N
The drugmaker plans to raise U.S. investments by 25%, totaling $55 billion, over the next four years. It plans to build four plants, including one at Wilson, North Carolina, and another at Tokyo-based Fujifilm Biotechnologies' manufacturing site in Holly Springs, North Carolina, over the next 10 years.
Locations for the other plants remain undisclosed.
Roche ROG.S
The Swiss drugmaker said in April last year it will invest $50 billion in the U.S. over the next five years.
A month later, it announced an additional $550 million investment to expand its Indianapolis diagnostics manufacturing hub. The expansion will span Indiana, Pennsylvania, Massachusetts, and California, creating more than 12,000 jobs.
In January, Roche said it will more than double its investment in its drug manufacturing facility in Holly Springs, North Carolina, to about $2 billion, up from the over $700 million announced in May 2025.
AstraZeneca AZN.L
The Anglo-Swedish drugmaker will invest $50 billion on U.S. manufacturing by 2030. The investment will fund a new drug substance facility in Virginia, its largest single-site global investment, alongside expansions in Maryland, Massachusetts, California, Indiana and Texas.
It has already started technology transfers and is managing inventory in 2025 to minimize any tariff hit. Company executives have said the impact would be "very short-lived."
Novartis NOVN.S
The Swiss drugmaker plans to spend $23 billion to build and expand 10 facilities in the U.S. over the next five years. This includes building six new manufacturing plants and expanding its San Diego research and development site, which is expected to create more than 1,000 jobs.
Sanofi SASY.PA
The French drugmaker plans to invest at least $20 billion in the U.S. through 2030 to boost manufacturing and research. Sanofi plans to expand its U.S. manufacturing capacity through direct investments in the company's sites and partnerships with other domestic manufacturers.
Chief Financial Officer François Roger said in July the potential tariffs are expected to have a limited impact in 2025, as the company already has inventory in place in the U.S.
Biogen BIIB.O
The U.S. drugmaker will invest $2 billion more in its existing manufacturing plants in North Carolina, adding capacity for gene-targeting therapies and automation. The company has seven factories in the state, with an eighth set to begin operations in late 2025.
Merck MRK.N
The U.S. drugmaker has begun building a $3 billion pharmaceutical manufacturing plant in Virginia as part of its over $70 billion investment to expand domestic manufacturing and research and development in the United States.
It will also invest $1 billion in a new Delaware plant to make biologics and cancer drug Keytruda, to boost U.S. production and potentially create over 4,500 jobs. It also opened a $1 billion facility at its North Carolina site in March.
Merck's animal health unit will invest $895 million to expand its Kansas manufacturing and R&D site, part of a broader $9 billion U.S. investment through 2028.
CEO Robert Davis in July flagged minimal impact from potential tariffs in 2025, and that the company remained well-positioned due to inventory management and moving of manufacturing to the U.S.
Amgen AMGN.O
The U.S.-based biopharma firm plans to invest $900 million to expand its Ohio manufacturing facility, bringing total investment in the state to $1.4 billion and adding 750 jobs. In December, the company committed $1 billion to build a second facility in Holly Springs, North Carolina.
Amgen said in September it is investing more than $600 million to build a new research and development center at its headquarters in Thousand Oaks, California.
The drugmaker announced it will invest $650 million to expand drug manufacturing at its facility in Juncos, Puerto Rico, a move expected to create nearly 750 jobs.
Novo Nordisk NOVOb.CO
The Danish pharmaceutical company said in August its strong U.S. manufacturing footprint positions it well for tariff challenges, describing itself as "very U.S.-centric and U.S.-focused".
AbbVie ABBV.N
U.S. drugmaker AbbVie ABBV.N said in January it has committed $100 billion over the next decade to U.S.-based research and development as part of its three-year deal with the Trump administration to reduce drug prices.
It has 11 manufacturing sites in the U.S. and has said it is "fairly insulated" from any tariff impact this year given inventory management actions.
Gilead Sciences GILD.O
Earlier this year, the drugmaker announced $11 billion in new planned investment in the U.S. to add to its domestic manufacturing and research heft, taking its total pledged investment to $32 billion.
Gilead said in September that it started work on a pharmaceutical development and manufacturing hub at its headquarters in Foster City, California, in addition to which, it is currently developing two other sites.
Cipla CIPL.NS
The Indian drugmaker is expanding its U.S. manufacturing footprint by investing in capacity expansion for complex respiratory products at its advanced facilities in Fall River, Massachusetts, and Central Islip, New York.
CSL CSL.AX
Australia's CSL said in November it would invest $1.5 billion in the U.S. to manufacture plasma-derived therapies, expanding its footprint in the country over the next five years.
(Reporting by Siddhi Mahatole, Kamal Choudhury, Puyaan Singh, Sneha S K and Sahil Pandey in Bengaluru; Editing by Tasim Zahid, Sahal Muhammed and Maju Samuel)
(([email protected];))
More Large Cap Ideas
See similar 'Large' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Cipla do?
Cipla is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company has its wide network of manufacturing, trading and other incidental operations in India and International markets.The company offers complex products at affordable prices, serving patients with innovative respiratory drugdevice combinations, complex formulations and a wide array of capabilities across injectables, oral solids and inhalation therapies. The company strategically leverages opportunities while managing risks.
Who are the competitors of Cipla?
Cipla major competitors are Dr. Reddy's Labs., Zydus Lifesciences, Lupin, Mankind Pharma, Aurobindo Pharma, Torrent Pharma, Alkem Laboratories. Market Cap of Cipla is ₹1,17,699 Crs. While the median market cap of its peers are ₹1,09,676 Crs.
Is Cipla financially stable compared to its competitors?
Cipla seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Cipla pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Cipla latest dividend payout ratio is 27.07% and 3yr average dividend payout ratio is 25.68%
How has Cipla allocated its funds?
Companies resources are allocated to majorly productive assets like Plant & Machinery
How strong is Cipla balance sheet?
Balance sheet of Cipla is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Cipla improving?
The profit is oscillating. The profit of Cipla is ₹3,879 Crs for Mar 2026, ₹5,273 Crs for Mar 2025 and ₹4,122 Crs for Mar 2024
Is the debt of Cipla increasing or decreasing?
The net debt of Cipla is decreasing. Latest net debt of Cipla is -₹2,312.07 Crs as of Mar-26. This is less than Mar-25 when it was -₹1,500.02 Crs.
Is Cipla stock expensive?
Yes, Cipla is expensive. Latest PE of Cipla is 30.33, while 3 year average PE is 28.33. Also latest EV/EBITDA of Cipla is 19.68 while 3yr average is 17.63.
Has the share price of Cipla grown faster than its competition?
Cipla has given lower returns compared to its competitors. Cipla has grown at ~12.06% over the last 3yrs while peers have grown at a median rate of 24.5%
Is the promoter bullish about Cipla?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Cipla is 29.21% and last quarter promoter holding is 29.21%.
Are mutual funds buying/selling Cipla?
The mutual fund holding of Cipla is decreasing. The current mutual fund holding in Cipla is 18.66% while previous quarter holding is 19.21%.